

IN THE STATE COURT OF CHATHAM COUNTY
STATE OF GEORGIA

RYAN MacADAMS, A MINOR, BY
AND THROUGH HIS NATURAL
GUARDIAN AND PARENT AS NEXT
FRIEND, DAWN MacADAMS,

Plaintiffs,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D., AND SAVANNAH SOUTHSIDE
CLINIC, P.C.,

Defendants.

CIVIL ACTION NO.
I-97-1091-G
[JURY DEMANDED]

COPY

DEPOSITION OF MICHAEL S. RADETSRY, M.D.

January 25, 1999

2:30 p.m.

500 Marquette Avenue, Northwest, Suite 280
Albuquerque, New Mexico

PURSUANT TO THE GEORGIA CIVIL PRACTICE ACT, this
deposition was:

TAKEN BY: **MR. FREDERICK S. BERGEN**
Attorney for the Plaintiffs

REPORTED BY: **DANNA SCHUTTE EVERETT, RPR, NM CCR #139**
Bean & Associates, Inc.
Professional Court Reporting Service
500 Marquette Avenue, Northwest, Suite 280
Albuquerque, New Mexico 87102

JOB NO. 5500-6 (DSE)

SANTA FE OFFICE
119 East Marcy, Suite 110
Santa Fe, NM 87501
(505) 989-4949
FAX (505) 820-6349

BEAN & ASSOCIATES, Inc.
PROFESSIONAL COURT
REPORTING SERVICE

MAIN OFFICE
500 Marquette NW, Suite 280
Albuquerque, NM 87102
(505) 843-9494
FAX (505) 843-9492
1-800-669-9492

A P P E A R A N C E S

For the Plaintiffs:

MR. FREDERICK S. BERGEN
Marist Place, Lafayette Square
123 Charlton Street, East
Savannah, Georgia 31401-4603

For the Defendants:

BOUHAN, WILLIAMS & LEVY
The Armstrong House
Bull & Gaston Streets
Savannah, Georgia 31498-1001
BY: **MR. PETER D. MULLER**

I N D E X

PAGE NUMBER

MICHAEL S. RABETSKY, M.D.

Examination by Mr. Bergen

5

Certificate of Completion of Deposition

123

Deponent Signature/Correction Page

125

EXHIBITS MARKED OR FORMALLY IDENTIFIED

1 - Notice to Take Deposition

5

4 - Curriculum Vitae

114

2 - Handwritten notes

122

3 - Responses to Plaintiffs' First
Interrogatories

122

SANTA FE OFFICE
119 East Marcy, Suite 110
Santa Fe, NM 87501
(505) 989-4949
FAX (505) 820-6349

BEAN
ASSOCIATES, Inc.
PROFESSIONAL COURT
REPORTING SERVICE

MAIN OFFICE
500 Marquette NW, Suite 280
Albuquerque, NM 87102
(505) 843-9494
FAX (505) 843-9492
1-800-669-9492

1 MR. BERGEN: This will be the deposition of
2 Michael Radetsky, M.D., taken in the MacAdams vs.
3 Poleyhard case. The deposition is taken pursuant to
4 notice and agreement of counsel, if any, for all purposes
5 allowed under the Georgia Civil Practice Act.

6 Reserve all objections except as to form and
7 responses, if that's agreeable.

8 MR. MULLER: Yes.

9 MR. BERGEN: Dr. Radetsky, I assume you want to
10 read and sign your deposition?

11 THE WITNESS: I would like to.

12 MR. BERGEN: It's agreeable to sign before a
13 notary here in this state or if you're traveling.

14 THE WITNESS: That's fine.

15 MR. BERGEN: No problem.

16 THE WITNESS: Did you want me sworn in?

17 MR. BERGEN: We'll do that in just a minute.

18 We're going to stipulate to the qualifications
19 of the court reporter and the means and manner of taking
20 deposition.

21 Are there any other qualifications that need to
22 be stated?

23 MR. MULLER: That's fine.

24

25

* * * * *

MICHAEL S. RADETSKY, M.D.,

after having been first duly sworn under oath, was
questioned and testified as follows:

EXAMINATION

BY MR. BERGEN:

Q. Dr. Radetsky, as you know, I'm Fred Bergen. I
represent Mrs. MacAdams on behalf of her son in this
lawsuit that's been filed in Savannah.

I sent you a notice to take your deposition, and
I understand you brought your file materials connected
with this case. Is that what you brought with you today?

A. Yes, sir.

Q. Let me just do this. Let's go through the
Notice to Take Deposition, which I'll attach as Exhibit 1
to this deposition.

(Exhibit 1 marked.)

Q. And do you have with you all letters you have
received from Mr. Muller or any member of his law firm or
any representative of the Illinois National Insurance
Company related to your review of materials relative to
this case?

A. Yes.

Q. Where is that correspondence?

A. They're all in my working file. In fact, just

1 to orient you, these are the records I was sent,
2 including depositions, and then my working file has
3 everything else in it.

4 Q. It might be easier, instead of going through
5 each and every one, I'll just look at what you have, and
6 if I have any questions --

7 MR. MULLER: Actually, I think, Fred, I think to
8 speed things up, I think there's probably a -- Well,
9 actually, is this all one thing?

10 THE WITNESS: That's Johns Hopkins.

11 MR. MULLER: I thought everything was mixed in.

12 Q. That's the Johns Hopkins records you've been
13 provided. Depositions? Deposition of Dawn MacAdams,
14 Harvey Kessinger, Gail Kessinger, Blake Poleyndard, M.D.,
15 Fernando Perez, M.D., Dr. Meislin, M.D., Charles
16 Schleien, M.D. Okay. So those are the depositions you
17 reviewed in this case?

18 A. Yes, sir.

19 Q. And then some document production, Schleien
20 hospital records; it looks like more Schleien hospital
21 records; Dr. Cohn's records of Ryan MacAdams. This is
22 from the Greater Baltimore Medical Center records, the
23 Memorial records. Anything else?

24 A. And then in my working file, what I did was to
25 take out certain records so that there would be more

1 available to me. Here's all the St. Joseph's records
2 here for the two emergency department visits, and then
3 selected records from Memorial Hospital and from Johns
4 Hopkins, which I pulled out just to have in my working
5 file.

6 Q. Okay. And then there's also Montgomery General
7 Hospital records. Also, I see some literature search,
8 some articles. What else?

9 A. Yes. Well, your request of me was to bring all
10 medical or scientific literature or sources that I used
11 in my analysis of Ryan. I must tell you, sir, in all
12 frankness, since my area is infectious disease, issues
13 regarding severe infections, meningococcal infections,
14 and children with fevers are part of my daily scholarly
15 life, and, therefore, I brought to bear much more in
16 terms of general literature than is in this folder.

17 But I did bring what I thought were either the
18 leading articles or articles which I felt shed light on
19 the case. But I just want to make the statement that
20 this is not an exclusive compiling of articles. These
21 are the articles I felt were most relevant.

22 Q. I understand. I take it, then, because of your
23 area of interest and expertise, you have like a working
24 file on pediatric fevers and things of that nature, but
25 case specific for this file, would these be the articles

1 that you have referenced?

2 A. well, these are the article's I feel are most
3 relevant.

4 Q. Okay.

5 A. But I do use information contained in other
6 articles because they're part of my daily scholarly life.

7 MR. MULLER: Also, I got the impression from his
8 answer there are articles that may not be in a file out
9 there that he's seen that could come to bear on it, but,
10 obviously, he couldn't have all of them with him today
11 because he reads them.

12 Q. There is a vast amount of literature on the
13 subject matter. I understand that. Let's just look at
14 ones that you've got with you today.

15 A. Sure. I'll just give you the lot of them, and
16 then you can certainly go through.

17 Q. In one of the copied articles, you have some
18 handwriting on the "Epidemic Meningococccemia and Purpura
19 Fulminans with Induced Protein C Deficiency."

20 A. Yes.

21 Q. Is that relative to this case, or is that just
22 some general working knowledge, you had your handwriting
23 on top of that article?

24 A. When I first reviewed that case, I took notes on
25 the article for myself, and they're, of course, on the

1 original, so they copied when I made a Xerox copy of
2 them.

3 Q. Why don't we do this, if you don't mind. I'd
4 like to get a copy of these. And why don't I just get
5 you to read the titles and lead authors, and then we can
6 move on. Okay?

7 A. Okay. Sure.

8 Q. I'll get a copy before we leave today.

9 A. "Osteonecrosis Following Meningococemia and
10 Disseminated Intravascular Coagulation in an Adult: Case
11 Report and Review"; lead author, Wayne N. Campbell.
12 "Epiphysiometaphyseal Changes in Children after Severe
13 Meningococcal Sepsis"; lead author, Francisco Fernandez.
14 "Late Sequelae of Infantile Meningococemia in Growing
15 Bones of Children"; lead author, Heidi Patriquin.
16 "Skeletal Lesions Following Meningococemia and
17 Disseminated Intravascular Coagulation"; lead author,
18 Minhard Robinow. "Incidence of bacteremia in infants and
19 children with fever and petechiae"; lead author, Kenneth
20 Mandl. "Epidemic Meningococemia and Purpura Fulminans
21 with Induced Protein C Deficiency"; lead author, Darlene
22 Powars. "Experimental treatments of meningococcal
23 sepsis"; Michael Levin.

24 Then there is a series of slides which I
25 compiled for a talk some time ago that recount

1 information from a number of other articles, and I just
2 gave you a copy of the handout.

3 Q. Okay.

4 A. "Febrile children with no focus of infection: a
5 survey of their management by primary care physicians";
6 lead author, Ronald Jones. "Practice Guideline for the
7 Management of Infants and Children 0 to 36 Months of Age
8 With Fever Without Source"; lead author, Larry Baraff.
9 And finally, "The febrile infant and the assumption of
10 risk," and I'm the author.

11 Q. You've got some correspondence in your next
12 section of your file?

13 A. Well, actually, to begin with, I had some notes
14 that I took that you wanted me to bring.

15 Q. All right. Thank you.

16 All right. The notes appear to be your notes
17 taken from the ER admissions -- the two ER admissions at
18 St. Joseph's.

19 A. That's correct.

20 Q. We'll just get a copy marked as an exhibit. If
21 you need to refer to them in the deposition, that's fine

22 A. The remainder are invoices, correspondence, and
23 a canceled check.

24 Q. When were you first contacted in this case? Was
25 it May *of* 1998?

1 A. I honestly don't know, sir. It would be around
2 the time of the first correspondence.

3 Q. Okay. That's what I was trying to make out. It
4 may be May 14th. It says, "I appreciate your willingness
5 to look at the file for me." For Mr. Muller.

6 A. Yes.

7 Q. The only invoice that you have submitted so far
8 is one -- it looks like May 27th of 1998. Is that the
9 only invoice so far to date?

10 A. Yes, that's the only one.

11 Q. I take it there's been additional work since
12 then?

13 A. Yes.

14 Q. And your charge was \$350 per hour for case
15 review?

16 A. It is.

17 Q. Does it change in any degree for depositions?

18 A. Deposition time itself is \$400 an hour, and
19 trial testimony at \$450 an hour.

20 Q. What about travel?

21 A. Travel is \$350 an hour with a maximum of 12
22 hours per day.

23 Q. So it's not portal-to-portal, but it could be
24 for travel, I take it?

25 A. That's correct.

1 Q. So during travel and trial testimony, it's
2 generally 12-hour days?

3 A. Yes. What I do is, actually, I bill
4 door-to-door with a maximum of 12 hours a day, and that's
5 in addition to the actual time I spend testifying. And
6 it usually works out that way.

7 Q. Okay. Let's put this aside. I'll get copies of
8 these letters, as well, later when we take a break or
9 after the deposition.

10 At the time of your first invoice, May 27th of
11 1998, were your opinions final in this case?

12 A. Let me just look at that first invoice, if I
13 could.

14 Q. Sure.

15 A. No. My opinions weren't final in the sense that
16 I had not read the depositions of any of the
participating individuals, both the family and the
18 doctors, so my expression of an opinion was based,
19 really, just on my record review, And then I think I
20 mentioned at the time that I would like to reread the
21 further depositions, and if there were a revision in my
22 opinions, then I would certainly be contacting them if
23 that took place, based on a review of depositions, which
24 I had not at that time received.

25 Q. Okay. You provided me a copy of your CV. I

1 understand the one I have in my hand is the most current
2 one. Correct?

3 A. That's correct.

4 Q. Let me see if it compares to the one that I
5 have, if I can find it. This one was apparently faxed --
6 it was probably a little bit out of date. It was May of
7 1998 -- from you, I guess to Mr. Muller. Would the only
8 additions be with regard to publications?

9 A. I think there's been an addition in
10 publications. I think I've gotten a couple more honors.
11 I haven't gotten the Nobel Prize or anything like that.

12 Q. Okay. I understand. Let me ask you this now.
13 What's your present address now, home address?

14 A. My home address?

15 Q. Yes.

16 A. 1217 Rockrose Road, Northeast, in Albuquerque,
17 87122.

18 Q. And you're still at Lovelace Health Sysseems, I
19 take it?

20 A. Yes. Actually, we say Lovelace.

21 Q. Lovelace, I'm sorry.

22 A. It's the way the founder pronounced his name.

23 Q. He's the one that gave the bread, so you do it
24 the way he wants to hear it.

25 A. That's right. That's the way.

1 Q. I see you went to law school at some point. It
2 looks like you graduated from Harvard in 1967. Is that
3 correct?

4 A. Yes. And I went to law school for one year, in
5 1967 to 1968.

6 Q. Why is that? What happened there?

7 A. Well, I went to law school because I thought
8 that that's what I was going to be doing with my life.
9 At the end of that first year of law school -- And it was
10 a tumultuous year because of the fact that Martin Luther
11 King and Robert Kennedy were both shot during that year,
12 It was the only year in the history of Harvard Law School
13 that final examinations were not given because of the
14 multiple murders of esteemed people, and it was a time of
15 some disillusionment for some of us, so I took a leave
16 of absence and enlisted in the United States Peace Corps.

17 Q. And you went into the Peace Corps. And you're
18 going to have to help me with this word.

19 A. I was a malariologist in the Peace Corps.

20 Q. Was that for malaria or something?

21 A. Yes, there was a malaria eradication campaign
22 run by the World Health Organization in Thailand, and I
23 was a middle-level bureaucrat from this particular
24 system.

25 Q. How old were you then?

1 A. Twenty-one, twenty-two.

2 Q. And then you went -- What is this? What is the
3 Alternative National Service (Conscientious Objection)?

4 A. I was drafted after I left the Peace Corps, but
5 there was a provision in the Selective Service law that
6 was passed after the Second World War that if, in
7 relationship to a supreme being, an individual was
8 conscientiously opposed to war in any form, and if thac
9 belief was validated by their local draft board, they
10 would be granted alternative service in the national
11 interest outside of the military, and that was my
12 situation.

13 Q. So, in other words, you objected to the Vietnam
14 War?

15 A. No, I objected to my participation in war in any
16 form.

17 Q. Regardless of whether it was Vietnam or any type
18 of war?

19 A. That's correct.

20 Q. Were you drafted?

21 A. I was drafted, but rather than going into the
22 military then, I worked at the Children's Hospital in
23 Boston.

24 Q. Did you avoid the draft?

25 A. I didn't avoid the draft. The way the Selective

1 Service law read was that if you were drafted but you
2 were a conscientious objector, you would perform national.
3 service in a nonmilitary capacity for the duration of
4 your obligation.

5 Q. Would law school grant you a college deferment
6 for the Vietnam War?

7 A. Yes, education granted you a deferment as long
8 as you were continuously in an educational institution.
9 But when you were not, then, of course, you were fully
10 eligible to be drafted.

11 Q. And so when you took your leave of absence from
12 the Harvard Law School, was that on good standing?

13 A. Yes, it was. And, in fact, I was invited to
14 come back, but as one thing leads to another thing, I saw
15 the light and went into medicine instead.

16 Q. But that leave of absence was a voluntary
17 decision by you?

18 A. It was.

19 Q. If you did not go into the Peace Corps or the
20 conscientious objection program, then you would have been
21 required to serve a military commitment?

22 A. Well, I was drafted, and if I had not been
23 granted the status of conscientious objection, then I
24 would have served military service rather than
25 alternative service. In either case, I was drafted.

1 Q. Why did you go to school in Canada in 1973?

2 A. Right. When I was applying to medical school, I
3 was accepted both in the United States and in Canada, and
4 Canada being the only country which has total reciprocity
5 with the United States, so you're not a foreign medical
6 graduate, and Americans would go to Canadian schools, and
7 Canadians would go to American schools. My decision to
8 go to Canada was that the tuition was \$800 a year

9 Q. Was it anything to do with avoiding the draft at
10 all?

11 A. No. I had already been drafted and had served
12 my obligation, but as a conscientious objector in
13 alternative service. So this was after my draft
14 obligation.

15 Q. Did you have to take the FLEX exam if you go to
16 Canada?

17 A. No. You take the national examinations just the
18 way American students do. It's not considered to be a
19 separate system from the point of view of licensure

20 Q. Then I take it, it appears that after medical
21 school and your rotating internship, your focus is on the
22 the area of pediatrics and in infectious diseases

23 A. That's correct.

24 Q. What did you do as the malariologist in

25 Thailand? Obviously, you worked not -- you weren't a

SANTA FE OFFICE
119 East Marcy, Suite 110
Santa Fe, NM 87501
(505) 989-4949
FAX (505) 820-6349

PEAN
ASSOCIATES
PROFESSIONAL COURT
REPORTING SERVICE

MAIN OFFICE
Marquette NW, Suite 280
Albuquerque, NM 87102
(505) 843-0494
FAX (505) 843-0492
1-800-669-9492

1 doctor at that time. What were you doing, exactly? I'm
2 trying to get a feel for that.

3 A. The program I was involved in was run by the
4 World Health Organization, and we were given three months
5 of training in Manila at the WHO center for malaria
6 eradication there to acquire the organizational and
7 laboratory skills whereby we could be put into an
8 existing program and contribute to the work of
9 eradication of malaria.

10 In my area of Thailand, which was up near the
11 Laotian border where Laos, Burma, and Thailand come
12 together, i supervised DDT spraying crews, supervised
13 crews that would obtain blbod samples from villagers to
14 see who had malaria, and then the distribution of malaria
15 medication to eradicate the infection. And this was the
16 three-pronged attack that the World Health Organization
17 had used successfully in other countries.

18 Q. And that was satisfying the conscientious
19 objection issue?

20 A. No. When you were in the Peace Corps, you were
21 given a deferment for the draft. The minute I left, the
22 Peace Corps, I was drafted.

23 Q. And then you went into the alternative national
24 service?

25 A. That's correct. I worked in a hospital in

1 Boston.

2 Q. And that was a -- Was there a local draft board
3 that had to approve that or --

4 A. Yes, the local draft board, which for me was in
5 Denver, had to do two things. They had to grant you the
6 status of being a conscientious objector -- and I was the
7 first, and to my knowledge the only, one ever granted by
8 my draft board -- and secondly, once you were drafted,
9 you had to work in a civilian capacity in a way that
10 contributed to the national service, really, and so they
11 had to approve your site where you found work that was
12 acceptable under the guidelines that they published.

13 Q. Okay. Then in 1982/1987 you were the associate
14 director of infectious disease at Denver General?

15 A. Actually, the Denver Children's Hospital.

16 Q. Did you have any interaction with Dr. -- Is it
17 Barkin?

18 A. Well,, I knew Dr. Barkin during the time that I
19 was in Denver. He's still in Denver, but I moved away.

20 Q. Then you moved on to Tucson?

21 A. Well, I was engaged to be married, and my wife,
22 who is a pediatrician, was going to do her internship in
23 Tucson, so I certainly wanted to be near her, and made
24 the move.

25 Q. Right. I understand. Did you know Dr. Harvey

1 Meislin out there then?

2 A. Yes, I did know him.

3 Q. Have you kept up with him since?

4 A. No, I haven't.

5 Q. Did you always get along with Dr. Meislin in
6 working out in Tucson?

7 A. I think, in all honesty, we probably only met a
8 few times. He primarily worked at University Hospital.
9 I primarily worked at Tucson Medical Center, although I
10 did work some at the University Hospital. He was
11 primarily in the emergency department. I was primarily
12 in the pediatric intensive care unit. So there weren't a
13 bot of places in which our practice lives overlapped.

14 Q. How about by consults?

15 A. Again, it was only infrequent, I must say, in
16 all honesty.

17 Q. And then back to Denver in 1989?

18 A. Well, yes. It was my hometown, and my wife was
19 able to transfer her training back to Denver, so we were
20 able to move back home.

21 Q. Then I see where you went to California for a
22 couple years. What was the reason for that?

23 A. Well, my wife, after she finished her pediatric
24 training, went to Johns Hopkins to get her master's in
25 public health. She then got a job in Sacramento at the

1 State Department of Public Health, which was one of the
 2 two plums in the United States. The other one being
 3 in Atlanta at the Centers for Disease Control. So I
 4 think I've spent most of my life following my wife
 5 around, and I went to California

6 Q. And then back here to Albuquerque?

7 A. Yes. In 1993, there was a budget crisis in
 8 California. You may have remembered

9 Q. Right.

10 A. They have a balanced budget amendment to their
 11 state constitution. She was last in/fixed out of her
 12 job. And was started looking for some other position in
 13 the west, where we were both from, and found it in
 14 Albuquerque.

15 Q. You were searching, and this is where you
 16 landed, so to speak?

17 A. That's correct.

18 Q. Have you ever had any problems at any hospitals
 19 where your privileges were denied, suspended, or revoked
 20 in any way?

21 A. Never.

22 Q. Have you ever been arrested or convicted of any
 23 crime of any type?

24 A. Never.

25 Q. Has any state ever revoked or suspended your

1 privileges --

2 A. Never.

3 Q. -- or your licenses?

4 A. Never.

5 Q. What family do you have here in Albuquerque?

6 A. None. Well, we have two children, but there are
7 just the four of us here.

8 Q. How old are your children?

9 A. Five and seven.

10 Q. First marriage?

11 A. First and only, I hope.

12 Q. Got around to having children eventually?

13 A. Well, we're late bloomers.

14 Q. I've got you. No family in Chatham County?

15 Some fellow we knew had the same last name, but no family
16 members from your side or your wife's side in Chatham
17 County?

18 A. No. My wife has a cousin who lives in Savannah.

19 Q. Who is that?

20 A. I'm trying to think of her name. I'm sorry.

21 It's Susan something, but I can't remember her last name.
22 Her husband is in real estate. I believe she is, as
23 well. But I just can't think of their last name. I'm
24 sorry.

25 Q. If you would ask your wife and maybe tell

1 Mr. Muller, he can let me know, or if it comes to you
2 later today in the deposition. Okay?

3 A. Sure.

4 Q. Have you ever practiced in Georgia?

5 A. No.

6 Q. I know you've spoken in several lectures. Have
7 you ever lectured in Georgia?

8 A. I don't believe I have.

9 Q. Have you ever been a party to a lawsuit before?

10 A. Is that a way of asking if I have been sued?

11 Q. Well, it doesn't matter. Either way. Have you
12 ever sued anybody, or has anybody ever sued you for any
13 reason? I'm going to boil it down to where it might --

14 A. I've been sued for medical negligence twice in
15 my life, but I've sued no one.

16 Q. Have you had any other type of litigation? Like
17 contract disputes, anything like that?

18 A. No.

19 Q. Where were the two cases where you were sued
20 regarding medical negligence?

21 A. These were two cases which arose during the time
22 that I was a pediatric resident in my training in Denver.
23 Both of them occurred in the early 1980s. And I was
24 named along with a large number of other people in each
25 of them, and I was discharged in both of them early on in

1 the proceedings of the lawsuit.

2 Q. What was the nature of the complaint?

3 A. The complaint in one of them was concerning a
4 seven-year-old girl who had kidney failure who was
5 admitted to the pediatric intensive care unit in which I
6 was working as a pediatric resident who, in the early
7 morning hours after her admission, had a cardiac arrest,
8 and the allegation was that it should have been
9 anticipated and it should have been conducted in a more
10 expeditious manner.

11 The second one was a child who had an unusual
12 condition, called hemolytic uremic syndrome, who was at
13 the Children's Hospital of Denver and who went into
14 kidney failure and needed to be transferred to the
15 University of Colorado where the dialysis unit was. I
16 dictated the transfer summary. Later on, he developed a
17 blood clot in his hand, and it was thought that the
18 catheter that he had in his radial artery contributed to
19 the blood clot, and he lost a portion of a finger, as I
20 recall. And I was named along with everyone else who had
21 ever cared for him.

22 Q. Those are the only two times a claim has ever
23 been made against you?

24 A. That's right.

25 Q. That includes any sort of notice of claim,

1 regardless of whether it concluded in suit or not?

2 A. I've never been noticed.

3 Q. Now, you've had experience in testifying in
4 medical/legal cases serving as an expert witness before,
5 have you not?

6 A. Yes.

7 Q. Let's talk about -- On how many occasions have
8 you?

9 A. Well, I started reviewing cases in 1982 when I
10 first went into the faculty of the Children's Hospital,
11 and in the 17 years I have probably reviewed 200 to 250
12 cases overall.

13 Q. So a little bit more than -- What's that come
14 out to a year?

15 A. Averages 10 to 15 a year.

16 Q. That's what I was going to say. Ten is a little
17 light, and 15 is about -- Between 10 and 15 a year? And
18 where have those cases -- To your knowledge, which states
19 have they been in?

20 A. Well, they've arisen from many states, frankly.
21 I think the bulk of them have been in the western states,
22 but I have been consulted by attorneys who represented
23 clients from many states, both in the east and in the
24 southeast.

25 Q. Let's talk about which states you recall

1 particular

2 A. I'm going to compare a mental map of the United
3 States, and then I'll go through.

4 Q. Okay.

5 A. Hawaii, Washington state California Idaho
6 Nevada Arizona Mexico Colorado Wyoming Montana
7 I can't recall Texas Kansas South Dakota Wisconsin,
8 Illinois, Missouri, Mississippi, Tennessee, Kentucky
9 Florida, Georgia, North Carolina, New Jersey,
10 Connecticut.

11 Q. Okay.

12 A. Oh, and Ohio. I'm sorry, sir.

13 Q. Thank you.

14 A. And I may have missed something in there, but I
15 tried to do my best.

16 Q. I appreciate it. And in each of those states
17 have you testified by deposition as well?

18 A. I don't think in each of those states I've
19 testified by deposition necessarily, but I can't recall
20 specifically which.

21 Q. How about trials? In which states have you
22 testified in courtrooms?

23 A. Hawaii, California, New Mexico, Idaho,
24 Colorado, Kansas, Illinois, Florida, Georgia, North
25 Carolina, Kentucky, and New Jersey. I believe, are the

only ones.

Q. In Georgia, where did you testify in Georgia?

A. In Atlanta.

Q. Okay. And do you know what the name of the case was?

A. Yes, Adams versus Kaiser.

Q. Which side were you on?

A. I was retained by the attorneys representing the defendant Kaiser-Permanente.

Q. Mr. Pound in Austin appeared in that case?

A. Excuse me?

Q. Was that Mr. Pound, Ted Pound?

A. I believe he was involved. That was the law firm. But the lead attorney was a female attorney, and I just don't remember her name. I'm sorry.

Q. Was that a meningitis case?

A. No, it was a meningococemia case in a child that had a cardiac arrest in a car going to the hospital.

Q. And that was in favor of the plaintiff for like a hundred --

A. A considerable verdict.

Q. Yeah. Do you remember Mr. Malone?

A. Oh, yes.

Q. Was that the only case you've testified in in Georgia?

1 A. I think so, sir.

2 Q. And what were you testifying -- What issues did
3 you testify to in that case?

4 A. The main issue was the issue of causation in
5 that case. The allegation on the part of the plaintiffs
6 was that the cardiac arrest that occurred meaningfully
7 led to the limb damage that this child suffered. I tried
8 to point out that the disease itself could have and
9 probably did cause all of the limb injury and that the
10 cardiac arrest itself did not increase the risk of limb
11 injury.

12 Q. Is that the only time you've testified in
13 Georgia?

14 A. I think it is, sir.

15 Q. How many cases are you currently reviewing?

16 A. I honestly don't know.

17 Q. Would it be on the 10-to-15-a-year range?

18 A. I think so. Sometimes there is a case that I
19 haven't heard about for a year or more, and I don't know
20 whether it's settled or not settled -- sometimes people
21 don't have the courtesy to let me know -- so it's hard to
22 estimate how many cases are truly active.

23 Q. Okay. But has that been your general case
24 review load, 10 to 15 a year?

25 A. I think that's the way it's averaged. I think,

1 as with all things, there are probably times that it's
2 been more and times that it's been less.

3 Q. Do you know how Mr. Muller got in touch with you
4 in this case, how he learned of you, or anything?

5 A. i don't know.

6 Q. Do you advertise your services in any way?

7 A. i do not.

8 Q. Have you generally had a reputation within your
9 area of expertise as someone who does get involved in
10 medical/legal cases?

11 A. I don't quite know how to answer that.

12 Q. Well, i mean, like if you may know someone who
13 reviews cases that you see at meetings and you might say,
14 "Well, you know, that guy reviews cases"?

15 A. Actually, I never know who is involved in case
16 reviews unless I've encountered them in the context of a
E7 lawsuit. It's not the sort of thing that's talked about
18 at professional meetings, at least not the ones that i go
19 to.

20 Q. What's your annual income regarding
21 medical/legal cases a year?

22 A. Well, I can't give you a -- I cannot give you a
23 dollar figure, but I would say that over the years it's
24 averaged, now, about 20 percent, perhaps in some years as
25 high as 25 percent of my total income.

1 Q. well, I mean, what would it be on the range of
2 an average year? Dollar figures?

3 A. I don't think I can give you that figure, sir.

4 Q. Well, do your tax returns report 1099's or a
5 different source of income per year?

6 A. Well, I will receive 1099's in any given tax
7 year, which I send to my accountant.

8 Q. I understand. But what I'm try to understand --
9 I'm just throwing numbers out. I mean, do you make
10 \$25,000? \$50,000 a year? A hundred thousand?

11 MR. MULLER: I don't think this is relevant.

12 MR. BERGEN: Sure is.

13 MR. MULLER: I don't think it is.

14 MR. BERGEN: Well, we can take it up with the

16 Q. I'm just trying to get a range of what your
17 annual income has been in medical/legal cases.

18 A. Well, I think the only way I can really answer
19 it is the percentage answer that I gave you, sir. I
20 can't give you any numbers.

21 Q. Who's your accountant?

22 A. I don't think I'm going to provide you with that
23 information, sir.

24 Q. So you refuse to tell me that information?

25 A. I'm not going to provide you with that

1 information.

2 Q. Do you know how many hours you spend a year in
3 medical/legal cases, review and otherwise?

4 A. Well, not exactly. This is all done on my own
5 time pretty much, either in the early morning or weekends
6 or whatever, or on a day off, like today.

7 Q. Are you able to estimate? That's all.

8 A. No, I can't give you a real estimate.

9 Q. As to your professional life, how do you break
10 it down into academics, hands-on, clinical, things of
11 that nature?

12 A. The Lovelace Clinic that I'm associated with was
13 founded in the 1920's by a fellow from the Mayo Clinic.
14 He wanted to make it the Mayo Clinic of the Southwest.
15 And it has always been an independent entity without the
16 strong presence of medical students or house staff, so we
17 do not have any intermediary individuals between us and
18 the patients. Consequently, of my 120 percent time, I
19 will spend about two-thirds of my time directly seeing
20 patients, both -- actually doing all three things:
21 ambulatory pediatrics -- I have my own clinic, my own
22 patients who grow up in my office; I do their primary --
23 hospital pediatrics, including a busy nursery, a busy
24 hospital ward; and I'm the only one trained to do
25 intensive care medicine.

1 Q. Is it a PIC unit, or is it considered a nursery?

2 A. It's a level 2 nursery. It does not -- Let me
3 put it this way. We have not elected to have long-term
4 ventilated patients there.

5 Q. Okay.

6 A. And then I do consultations in infectious
7 diseases. I also teach at the university, where I will
8 attend on their pediatric ICU and step-down unit and
9 teach in infectious disease, and then I have some
10 scholarly activities that I'm involved in. But since I'm
11 also the department chair, there's a lot of
12 administrative work that I must do, of course.

13 Q. So probably two-thirds patient care, one-third
14 academic and administrative?

15 A. I think that's a good breakdown.

16 Q. In the cases that you have testified in and
17 appeared as an expert witness, have you testified in any
18 cases where you've expressed an opinion that earlier
19 intervention would have made a difference in the outcome
20 of the patient with meningococcal infection?

21 A. I don't think I've been involved in a case in
22 which I felt the facts could lead me to that conclusion
23 regarding a meningococcal infection.

24 Q. Of the cases where you have testified in, how
25 does it break down plaintiff versus defendant, patient

1 versus doctor or medical center, whatever?

2 A. Sure.

3 MR. MULLER: Are you talking about he's
4 testified --

5 MR. BERGEN: Uh-huh.

6 MR. MULLER: -- in either deposition or at
7 trial?

8 MR. EERGEN: Yeah, deposition and trial.

9 A. Understanding, since I don't advertise, people
10 just call me, and the proportion in which they call has
11 very little to do with myself, it's just who ends up
12 contacting me, I'd say in terms of review of cases,
13 probably 80 to 85 percent have been sent to me by
14 attorneys representing defendants of one sort of another;
15 15 to 20 percent injured parties. At deposition, I would
16 say the disproportion increases. I'd say probably 90 to
17 95 percent of depositions are involved with my expressing
18 opinions supporting defendants in a lawsuit. And I've
19 only testified one out of 20 to 25 times at trial for an
20 injured party.

21 Q. What type of case was that time when you
22 testified for an injured party?

23 A. Bacterial meningitis.

24 Q. Where was that case?

25 A. Right here in Albuquerque.

1 Q. Do you remember the style of the case?

2 A. I do. It was called Little versus Parrino. I
3 think that's P-A-R-R-I-N-O.

4 Q. And do you know what court it was filed in in
5 Albuquerque?

6 A. I honestly don't know, sir. It was some years
7 ago.

8 Q. Of the 20 to 25 times you've actually testified
9 in court, only one occasion is where you testified for
10 the injured patient?

11 A. That's correct.

12 Q. And that was the Little case?

13 A. That's correct.

14 Q. And has most of your testimony been in cases
15 regarding causation or causal relationship or whether
16 earlier intervention would have changed the outcome? Has
17 that kind of been your area of expertise in testifying?

18 A. No, I wouldn't say so. As a practicing
19 physician, I'm called upon to express opinions on the
20 standard of care as well.

21 Q. Okay. Have you ever expressed any concern about
22 the medical/legal system where a plaintiff can sue a
23 defendant medical provider for compensation?

24 A. By "expressed," what do you mean?

25 Q. Well, in lectures or writings or letters to

1 editors, things of that nature.

2 A. Well, you understand, I've gone to law school
3 for at least a year, and I honor the system by which an
4 injured party can seek compensation. I have expressed in
5 writing in letters or -- primarily letters, I think --
6 that I feel that there is an untoward amount of
7 litigation directed towards doctors which, at least in my
8 experience, has been ill-founded in truth or science.
9 And I think in one letter I even called it rampant
10 litigation. But I think it is true that there are many
11 lawsuits that don't have merit that are filed. But I
12 certainly honor the lawsuits that do have merit.

13 Q. I think the rampant litigation statement dealt
14 with timing of meningococemia treatment. It was a
15 response to a doctor in Texas, an article done by some
16 physicians in Texas, a lady by the name -- I can't
17 remember her first name.

18 A. Yes, I think you're right, sir. It was a letter
19 written following the publication of a review article
20 regarding the experience of meningococcal disease at
21 Parkland General Hospital in Dallas.

22 Q. Right, timing of therapy for meningococcal
23 infection. It was a letter that you wrote after a review
24 of an article by Kirsh --

25 A. Yes.

1 Q. -- in which you referred to rampant litigation.

2 A. Yes.

3 Q. Any other articles or letters that you've
4 expressed this opinion that you can refer to?

5 A. Not, perhaps, in the same tone of voice, no.

6 Q. You've provided me a number of articles dealing
7 with the subject matter relative to Ryan MacAdams on your
8 opinions in this case. Is there any other sort of
9 standard textbook or treatise that you consider to be
10 authoritative considering this type of infection that
11 Ryan had?

12 MR. MULLER: Would you define "authoritative"
13 here?

14 MR. BERGEN: That he would consider to be
15 gospel. How about that?

16 MR. MULLER: I mean, because your doctor had a
17 specific feeling about it, and I didn't know whether you
18 were defining it the same way your doctor states if it is
19 an authoritative text, and that means that every single
20 thing in that text is gospel.

21 MR. BERGEN: That's right. I mean, basically,
22 it's a term *of* art, and it's a term of legal consequence.

23 MR. MULLER: You're talking about everything, is
24 there a text where everything in that text is gospel?

25 MR. BERGEN: Right.

1 A. I don't think so. Dr. Meislin put it nice when
2 he said textbooks are informative, but not authoritative.

3 Q. Do you agree with that proposition?

4 A. I would. He pointed out that many chapters are
5 written with some delay before they get published so
6 they're somewhat out of date, perhaps, and also you're
7 limited in your space and in the depth to which you can
8 probe in a textbook article, so you're always shying away
9 from controversies, and you're always, in a sense, just
10 reinforcing certain standard observations that may not be
11 entirely direct.

12 Q. It's a good reference source, but there can
13 be -- it can be out of date, things like that?

14 A. I think it's a good place to start if you know
15 nothing about a subject, but it's not the place to end.

16 Q. How about as to any literature that you consider
17 to be authoritative -- and I'm talking about
18 literature -- in the management of a febrile infant? And
19 I notice you had Dr. Baraff's article, the guidelines
20 that was in Pediatrics, I think, in 1984 --

21 A. It was 1993.

22 Q. I'm sorry' 1993. Excuse me. -- which had been
23 an accumulation of guidelines that had been in the works
24 for years, as I understand. Is that your understanding?

25 A. Well, Dr. Baraff and his colleagues tried to

1 create some order out of what they perceived to be
2 disorder, and come out with a viewpoint that could be a
3 source of guidance for practicing physicians, but as
4 you'll notice in the last paragraph of their article,
5 they very specifically state that theirs are not binding
6 recommendations; they're only a starting point, and that
7 every practicing physician should approach the individual
8 patient with individual analysis.

9 I've written a couple times on the febrile
10 infant. I think that the things that I said in my own
11 publications are my best attempt to approach it. It's an
12 area in which there are now over 800 or 900 separate
13 publications, and, therefore, it's one for which no
14 single publication can stand alone.

15 Q. Okay. And you anticipated my next question. I
16 guess you saw me look at your journals. I think you did
17 have one of your journal articles which dealt with the
18 clinical evaluation of the febrile infant and certain
19 recommendations that one might want to go through to
20 evaluate the febrile infant.

21 A. There have been two articles I've written about
22 that subject.

23 Q. I see one on primary care. What was the other
24 one?

25 A. I actually provided you a copy of it. Yes. It

1 was published in the Current in 1996.

2 Q. Is that the assumption of risk?

3 A. That is the one.

4 Q. Have you provided Mr. Muller with any written
5 reports regarding your opinions in this case?

6 A. No.

7 Q. Did you consult with any physician in
8 formulating your opinions in this case?

9 A. No.

10 Q. Did you discuss it with any other physician or
11 colleague?

12 A. No.

13 Q. To date, how much time do you think you have
14 spent in reviewing the materials and formulating your
15 opinions in this case? To date?

16 A. The only invoice I sent was for a total of
17 seven-and-a-quarter hours. I think that within the
18 additional materials sent to me, the depositions, the
19 preparation for this deposition, the travel time, there's
20 probably an additional 15 to 20 hours involved.

21 Q. Okay. So 23 hours, 24 hours would be
22 comfortable?

23 A. I think that order of magnitude, without being
24 held to an exact number.

25 Q. Sure. I understand. I'm just trying to get a

1 reference of how much time you've spent.

2 A. But I must say, in all fairness, there were a
3 considerable number of depositions, and the follow-up
4 hospital records here were quite complex because of the
5 nature of the child's injury.

6 Q. Did you make any notes in the deposition
7 transcripts or anything?

8 A. In the mother's deposition, I did some
9 underlining -- excuse me -- highlighting, and I don't
10 think I did it in anyone else's deposition than hers.
11 And then in some of the medical notes here I did some
12 highlighting. This would be an example on the page on
13 which I highlighted just some references to the rash,
14 which, of course, is a matter of contention in the
15 lawsuit.

16 Q. Okay. As to practice guidelines of a febrile
17 infant, a fever for an infant, I notice Dr. Baraff and
18 contributors talk about a low range of 100.4 rectal as
19 being a fever, and I notice in one of your articles you
20 give 100 degrees by mouth and 101 by rectum. I mean, I'm
21 asking you, where do you consider the cutoff point for
22 fever of an infant, definition of a fever of an infant of
23 Ryan's age? Is the scale zero to 36 months? Is that the
24 range you like to use, or is it a shorter time period?

25 A. I think the zero to 36 months is too large a

1 span because a freshly minted newborn you approach
2 differently than a child who's four months of age, that
3 this child almost was, or a child who's three years of
4 age.

5 But I should tell you, in all fairness, that the
6 definition of fever has no consistency about it, and it
7 has no agreed point. It is truly one of those arbitrary
8 thresholds. I will tell you currently what the two most
9 common breakpoints actually are.

10 Q. Okay.

11 A. One is 100.6 degrees Fahrenheit -- that's 38
12 degrees centigrade -- and the other is 101 degrees
13 Fahrenheit, or 38.3 degrees centigrade. But in truth, I
14 think the only reason that they're chosen is because they
15 are round numbers. One is 101, a round number Fahrenheit
16 number; the other is 38, a round centigrade number.

17 Q. From what we have in the chart regarding Ryan's
18 first emergency room admission, could you and I agree
19 that, from what's in the chart, at all times Ryan had --
20 would classify as having a fever?

21 A. He would.

22 Q. And by that definition, then, at all times, from
23 what we see in the chart, Ryan was a febrile infant in
24 the emergency room at St. Joseph's Hospital on the
25 afternoon of May 7th, 1992?

1 A. He was.

2 Q. And based upon your review of the chart, can we
3 agree that the fever that Ryan had was without known
4 source during that first emergency room visit?

5 A. Yes.

6 Q. With infants of Ryan's age that are febrile,
7 isn't there an -- there is a risk of bacteremia?

8 A. There is.

9 Q. And am I correct in this statement, that
10 meningitis is almost always preceded by a bacteremia?

11 A. That's correct.

12 Q. And isn't it agreed or thought medically in your
13 area of expertise that one of the reasons why you want to
14 determine if the patient may have bacteremia in an infant
15 of Ryan's age is so that you can treat it so it won't go
16 into possible meningitis? Am I making sense there?

17 A. Yes, although I think there's a broader
18 perspective than just that. Bacteremia most of the time
19 is self-resolving, but there will be children who will
20 have a progressive illness -- that is, septicemia -- or
21 in whom the bacteremia will lead to a focal infection.
22 And the idea there is to either try to terminate the
23 bacteremia before it progresses to a more severe
24 generalized infection or before it actually causes focal
25 infection,

1 Q. Okay.

2 A. Understanding that most cases of bacteremia will
3 resolve on their own.

4 Q. When you talk about a focal infection, you're
5 talking about a specific organism causing the disease?

6 A. No, what I meant by a focal infection, meaning a
7 focal part of the body or a specific part of the body.
8 For example, meningitis, a bone infection, a series of
9 places in which the infecting organism may lodge and then
10 cause disease in a particular organ.

11 Q. Well, Ryan had an occult bacteremia, did he not?

12 A. Well, a blood culture was not performed, as you
13 know, and, therefore, no one can know for sure whether on
14 his first visit he did, in fact, have a bacteremia.

15 Q. Knowing what we know now, looking back
16 retrospectively, would you agree that more likely than
17 not he did have a bacteremia when he first went to the
18 hospital?

19 A. I think he had a bacteremia at some point during
20 that three-hour stay in the emergency department,
21 because, as you point out, seven hours after his
22 discharge he's back with septicemia. And I think that in
23 retrospectively weighing the chances of a bacteremia
24 existing at the first ER visit, it would come out greater
25 than 50-percent likelihood.

1 Q. Would you agree, then, in infants older than two
2 or three months of age the higher the temperature, the
3 higher the risk of bacteremia occurs?

4 A. Yes.

5 Q. In the converse, of infants less than two to
6 three months of age, the height of the fever has no
7 relationship to the relationship of bacteremia?

8 A. I think I have to revise that now and probably
9 say less than one month of age.

10 Q. Okay.

11 A. The most recent information -- I think
12 Dr. Baraff talks about this as well. A child who is one
13 month of age or less is really quite different than a
14 child who is older than one month. And probably the
15 three-month differentiating point, which has been used
16 since the early 1970's when the first articles came out
17 about the febrile infant, is probably the wrong
18 differentiating point. It probably should be one month
19 of age.

20 And I might say in passing, sir, that although I
21 personally feel that the higher the fever the greater the
22 risk of bacteremia, there are some very capable people
23 who have published quite the opposite of that.

24 Q. But as to what you think, the height of the
25 temperature has a correlation to the increased risk of

1 bacteremia if the child is three months -- greater than
2 three months?

3 A. Yes, I believe so. But probably in light of
4 these conflicting publications, it's probably less
5 reliable than I thought it was at one point.

6 Q. Well, isn't it true that the medical literature
7 talks about that with each increase in degree of
8 temperature in an infant, the increased degree of risk of
9 bacteremia exists in three-to-eight-month age infants?

10 A. I don't think I understood that, sir. I'm
11 sorry.

12 Q. Okay. If the temperature -- high temperature in
13 a child who is three to eight months -- using that window
14 there --

15 A. Three to eight months?

16 Q. Three to eight months. -- that that puts them at
17 higher risk of bacteremia?

18 A. I don't know the literature that deals with an
19 age range of three to eight months. I'm just unfamiliar
20 with that.

21 Q. But greater than three months you're familiar
22 with?

23 A. Well, I'm familiar with the topic in general at
24 all ages, and it is my personal conclusion that at all
25 ages the height of the fever probably increases the risk

1 of bacteremia once you're above a month of age, but with
2 less reliability than I thought at a former time due to
3 the publications of articles which do contradict what
4 I've just told you.

5 Q. Let me ask you this. In 1992, the general
6 thought was greater than one month or greater than three
7 months with temperature increased the risk of bacteremia?

8 A. I think in 1992 most people thought that as a
9 general proposition the higher the fever, the greater the
10 risk. And understanding that even then it was known that
11 there were certain breakpoints. For example, a
12 temperature of 39 degrees -- greater than 39 degrees
13 seemed to have a distinctly different risk than
14 temperatures less than 39 degrees. That was based on an
15 old study, but a uniquely useful study, published in 1975
16 from Boston Children's Hospital -- excuse me -- from
17 Boston City Hospital. Of 600 consecutive patients seen
18 with fever, none of them had a bacteremia if their
19 temperature was less than 39 degrees.

20 And I think people felt somewhere around 104 to
21 105 there was another breakpoint. Above that break
22 level, the risk went up from the three- to four-percent
23 level to a higher level of maybe five, six, or seven
24 percent. But, of course, no one knew exactly where the
25 breakpoints were at 1992 or even today.

1 Q. Is cyanosis one of the clinical pictures of
2 toxicity in febrile infants?

3 A. Well, it's one of the items that people look for
4 in assessing the general state of an infant, but you'd be
5 looking for central cyanosis, not peripheral cyanosis.

6 Q. Would you agree that the standard of care in
7 1992 in all children from zero to 36 months with fever
8 without known source and with some toxic appearance
9 requires hospitalization with antibiotic treatment and
10 sepsis workup?

11 MR. MULLER: Objection to the form of the
12 question. Fails to define "toxic."

13 A. No, I wouldn't agree with that as a straight
14 statement.

15 Q. Okay. What do you consider to be toxic
16 appearance of children with bacteremia?

17 A. That's one of those words that's very hard to
18 define, "toxic," but the one -- the definition that I've
19 always used, which I think is the best, comes from a
20 pediatrician named Sidney Gellis, who was the chairman of
21 the department at Tufts for many years, and is now in his
22 eighties. When he was asked to define toxic, he said,
23 "It's the child who looks and acts damn sick." It
24 conveys, I think, what the issue is; that is, it's a
25 child who is distinctly unwell, more unwell than just the

1 height of the fever can account for, more unwell than the
2 time of day can account for, more unwell even than a
3 possible focus of infection can account for. And for
4 people who do this day in and day out and see any numbers
5 of children every day, that conveys a message.

6 Q. Do you agree with me that with the type of
7 disease that Ryan was known to have, that symptomatology
8 can change acutely? It can be a rapid-changing
9 condition?

10 A. A lot depends on the use of the word "rapid."
11 It is a dynamic illness, and children can become ill
12 progressively, but different individuals will become ill
13 at different rates,

14 Q. Okay. Well, you've read the deposition of
15 Mrs. MacAdams in this case, have you not?

16 A. I have.

17 Q. And you read where she testified that a rash was
18 present after Dr. Perez examined Ryan, but when
19 Dr. Poleynard came back in, it came on. Would that be
20 consistent with this type of disease that this child had,
21 to have a rash that suddenly appeared?

22 MR. MULLER: Is that the only thing that you're
23 asking?

24 MR. BERGEN: Yeah.

25 MR. MULLER: Is the sudden appearance of a

1 rash --

2 MR. BERGEN: Right.

3 MR. MULLER: -- consistent?

4 A. Well, I guess as a general truism, any child
5 that has a rash has to have a moment when that rash
6 appears. In that case it's instantaneous. It's no
7 different than any other illness, such as measles or drug
8 reaction or German measles. There's a point where you
9 don't have a rash; there's a point where you do have a
10 rash. I don't think it's any more abrupt here than it
11 would be in any of those other illnesses.

12 Q. When Ryan left the emergency room, more likely
13 than not you'd agree that the meningococemia had not
14 been diagnosed? He had an undiagnosed case of
15 meningococemia, more likely than not, when he left the
16 emergency room the first time?

17 A. Let me try to answer. When he left the
18 emergency room at 8:15 that night, I believe he had
19 meningococemia, but I do not believe he had
20 meningococcal bacteremia, which is a word that says
21 you're not only bacteremic, but you are also severely
22 clinically ill.

23 Q. Okay. He still would have had the presence of
24 the organism of Neisseria meningitidis?

25 A. Meningitidis.

1 Q. Thank you. That organism would have been
2 present in his blood?

3 A. I believe more likely than not that he had it in
4 his bloodstream.

5 Q. Do you have an opinion as to whether or not,
6 based upon what you have reviewed, Ryan should have been
7 admitted to the hospital during the first emergency room
8 visit?

9 A. I have an opinion.

10 Q. What is your opinion?

11 A. I don't believe there was an indication for
12 obligatory hospitalization, no.

13 Q. Do you have an opinion as to whether or not
14 antibiotics should have been used during the first ER
15 admission?

16 A. I have an opinion.

17 Q. And what's your opinion?

18 A. It's my opinion that the use of antibiotics was
19 an acceptable but not an obligatory management option.

20 Q. Okay. Now, if you suspect a child to have --
21 make sure I'm correct in this -- meningococcal
22 bacteremia, what do you consider the standard of care to
23 be to treat that condition if the patient presents -- I'm
24 talking about 1992 because that's what this case deals
25 with.

1 MR. MULLER: Object to the form of the question.
2 It's a hypothetical that fails to supply sufficient facts
3 for the doctor to form an opinion.

4 Q. You can go ahead and answer. With an infant of
5 Ryan's age.

6 A. Sure. I can't answer it because I don't know
7 what you mean by the word "suspect." It means different
8 things to different people.

9 Q. How about differential? In your differential
10 diagnosis?

11 A. The reason I have trouble with that is when
12 you're dealing with small children, you also suspect bad
13 things, If you find no evidence for them being present,
14 then you don't act upon them being present and,
15 therefore, no treatment would be necessary for a
16 suspicion. Only if someone had clinical disease would
17 you begin therapy.

18 Q. If clinical disease -- what do you mean by that?
19 "Clinical disease"?

20 A. Well, a child who had clinical septicemia. You
21 know, you can't look at the child and say when a child --
22 excuse me -- what organism may be causing the septicemia

23 Q. I understand that.

24 A. But if you saw a child who had clinical
25 septicemia or clinical meningitis, then there are

standard ways of treating those individuals. But
2 suspicion is not a word which has a common definition,
3 I'm afraid.

4 Q. Okay. Let's take the example where you believe
5 this child does have meningococcal bacteremia. What do
6 you do?

7 A. Well, if you believe the child has clinical
8 septicemia, because you don't know what might be causing
9 it until you get the results of your testing back --

10 Q. Right.

11 A. -- then the proper approach to that is first and
12 foremost to get the child to a place where they can deal
13 with serious illness in small children, You then
14 establish an intravenous line. You assess for the
15 presence or absence of respiratory failure and shock, and
16 if present, you deal with those first.

17 You obtain all the specimens that you will need
18 to diagnose the disease, which is your clinical
19 diagnosis. That would include under most circumstances a
20 blood culture, probably a urine culture, and if safe to
21 do so, a spinal tap, although it may not be safe to do so
22 at the particular time.

23 Q. Okay.

24 A. And then you would initiate antimicrobial
25 therapy. And there are a number of choices there.

Okay. Did you try to make a determination in
your mind as to whether or not a rash was present with
Dr. Poleyndard?

A. I tried to make a determination based upon the
available information which I possessed.

Q. Did you reach a conclusion, or are you not sure
one way or the other?

A. I think that the available information to me
suggests that no rash was present despite the fact that
the mother, in fact, does remember a rash being there. I
couldn't find confirmation of that reliably in the
contemporaneous notes written at the time that the child
became terribly ill and was admitted to the hospital and
so on.

Q. If a rash was present with Dr. Poleyndard based
on the patient's findings in the chart, would that change
what Dr. Poleyndard should have done in this case?

MR. MULLER: Object to the form of the question.
It fails to outline what you mean by "rash."

Q. You can go ahead and answer.

A. Well, if a rash is present in any child, the
child requires a reevaluation, and that's the only thing
that would have been required. And then based on the
reevaluation, then there might be different management
decisions made.

1 Q. If it was determined to be a petechial rash, a
2 nonblanching petechial rash, what would the standard of
3 care have required in this case?

4 A. The standard of care would have required a
5 reevaluation and a reexamination. One of the articles
6 that I supplied to you is an article from Boston
7 Children's Hospital looking at fever and petechial rashes
8 and how rare it actually is that that is a harbinger of a
9 serious illness. Consequently, a petechial rash is not
10 an uncommon finding in children with fevers due to many
11 different causes, but it does demand a reevaluation"

12 Q. Okay. And reevaluation, what does that include?

13 A. Well, it includes another systematic
14 examination. It may include repeat blood testing. The
15 child did have some blood testing done earlier on, but
16 that was at 7:15. It's now an hour or so later. That
17 would be an option. Blood culture could be obtained,
18 further period of observation could be obtained, the
19 child could have been given presumptive antimicrobials
20 and then sent home.

21 The child could have been admitted to the
22 hospital for observation only, The child could have been
23 admitted to the hospital for observation and
24 antimicrobials. There are a number of different choices
25 that one can make, and, of course, the goal is to try to

1 match the level of risk that you perceive in the
2 individual patient.

3 Q. This type of disease that Ryan had also can
4 demonstrate macular rashes, can it not?

5 A. It can.

6 Q. How do you describe a macular rash?

7 A. The definition of a macular rash is a flat
8 blanching red rash.

9 Q. And you would expect a physician practicing in
10 an emergency room in 1992 in the United States of America
11 to be able to differentiate between petechial and macular
12 rashes, would you not?

13 A. Yes.

14 Q. An emergency room physician practicing in the
15 United States in 1992 should recognize -- standard of
16 care would require that physician to be able to recognize
17 that macular rashes are associated with meningococcal
18 bacteremias?

19 A. That's an interesting question. The main
20 article that showed that was published in an English
21 journal in and around that time. It may even have been
22 after 1992. And I would not necessarily expect people to
23 associate macular rashes with meningococcal bacteremia in
24 1992, no.

25 Q. But ysu would?

A. That's my area of expertise.

Q. I understand. But there is a correlation between the two -- or can be -- a macular rash with meningococcal bacteremia?

A. Let me put it this way. The macular rash has been reported as being a rash seen at some stage in some patients in meningococcal bacteremia. But in the universe of rashes, it is an extremely rare component, and, therefore, a macular rash in an otherwise well-looking child would not raise the spectre of meningococcal disease in a patient.

Q. Can the macular rash also turn into the purpura-type rash --

A. Yes, it can.

Q. -- at later stages?

A. It can.

Q. In the macular rash, a forerunner is the purpura rash?

A. Not necessarily.

Q. Frequently, more often than not, a forerunner is the purpura rash?

A. Again, the macular rash is seen at times, but not commonly, in meningococcal disease. And in this particular case study that was done, many of those children did evolve their illness into either petechiae,

1 purpura, or both. But, of course, that is an evolution
2 of illness that is seen in children who have
3 meningococcal disease without a macular rash.

4 So it's unclear whether the rash is a precursor
5 or whether it is just another manifestation of the
6 disease. But as I say, it's an uncommon manifestation of
7 the meningococcal disease, and I would not want to raise
8 the spectre of meningococcal disease in a child who did
9 not look significantly ill.

10 Q. You and I can agree that a child such as Ryan
11 with -- a febrile infant such as Ryan of unknown source
12 who develops a rash in the emergency room -- that that
13 would at least -- standard of care -- require
14 reevaluation of the patient?

15 MR. MULLER: You're talking about a child
16 getting a petechiae rash?

17 MR. BERGEN: Just a red rash.

18 MR. MULLER: A diaper rash?

19 MR. BERGEN: I'm just asking about any rash on
20 his body. He's already told me rashes can develop
21 anywhere on the body.

22 Q. Does a rash raise a red flag in conjunction with
23 treating a febrile infant of Ryan's age, three-and-a-half
24 months?

25 A. As a general answer to a general question,

1 rashes can be clues to illness, and the rash certainly
2 should be looked at if it evolves in any setting, whether
3 it's in an emergency room or in a clinic or whether the
4 child comes in with a rash. It's another clue to illness
5 that should be evaluated, but it doesn't necessarily
6 demand a full reexamination of every body part.

7 Q. Do you agree with me that Dr. Poleyndard should
8 have gotten other temperatures on Ryan?

9 A. No.

10 Q. Okay. So the two temperatures that you see in
11 this case are adequate in your opinion?

12 A. Oh, sure. We would only get one temperature.

13 Q. Even after treatment?

14 A. Sure.

15 Q. So you would use just the temperature at
16 admission, at triage, in evaluating this patient?

17 A. That's correct. We seldom get a second
18 temperature on a child.

19 Q. Did you see where Dr. Poleyndard testified that
20 he gave another temperature but it wasn't recorded?

21 A. Yes, I saw that.

22 Q. If you take a temperature, don't you record it?

23 A. Well, I don't personally take temperatures of
24 anybody.

25 Q. Well, if you order it.

1 A. Again, I don't usually record it. It's usually
2 a nursing function, if it's recorded at all. A lot
3 depends, sir, on what the object is for taking the second
4 temperature. If it's to convince myself that I've waited
5 long enough for the child to get the fever down so the
6 parents wouldn't worry, that would be one thing; if I'm
7 using it as a diagnostic maneuver, that might be
8 something else.

9 As I said, we so seldom order or take second
10 temperatures that it's very hard to answer your question.

11 Q. Let me ask you this. As to Ryan, from your
12 review of the first emergency room visit, I understand
13 you've expressed opinions that you think Dr. Poleyhard
14 adhered to the standard of care during the first
15 admission.

16 A. Yes, I do.

17 Q. If you look at Ryan's material in the chart, he
18 was over three months of age at the time, correct?

19 A, Correct.

20 Q. He had a fever, by your own definition, at all
21 times?

22 A. Definitely.

23 Q. And if you take the additional fact of a rash
24 being present during the examination by Dr. Poleyhard, if
25 you take those triad of information, would you agree with

1 me that Ryan had in his differential a bacteremia?

2 MR. MULLER: I'm going to have to object to that
3 question.

4 MR. BERGEN: Why don't we just reserve all
5 objections to all hypotheticals? I know you're going to
6 object to all hypotheticals I give him.

7 MR. MULLER: Okay. I'm reserving all objections
8 to hypotheticals, including form of the question, which
9 would include, but not be limited to, that it gives facts
10 that aren't proven, that it doesn't give sufficient
11 facts, et cetera.

12 MR. BERGEN: Right, Anything as to not assuming
13 all facts in evidence will be reserved. Let's just
14 leave --

15 MR. MULLER: I may from time to time pipe up
16 anyway, such as this one where I have a problem with you
17 talking about a rash but not talking about what type of
18 rash.

19 Q. The rash that was described by Mrs. MacAdams in
20 her definition.

21 A. Sir --

22 Q. Do you want me to rephrase it?

23 A. No. Any child with a fever has a possibility of
24 having a bacteremia, sight unseen, but the level of risk
25 of bacteremia changes as you get more information

1 regarding the child. Physical information, observation,
2 laboratory testing.

3 So the answer to your question is generically
4 yes to any young child with a fever without an obvious
5 source, but the level *of* risk *of* that thought of
6 bacteremia or probability of bacteremia changes as you
7 gather more information during the period of evaluation.

8 And, of course, that's what your business is, is
9 to try to use physical findings, laboratory studies, and
10 the natural history to correctly assess what the risk
11 actually is.

12 Q. With a bacteremia, do you agree that one's white
13 cells can be consumed?

14 A. There are some children who have septicemia --
15 meaning clinical illness, so they look and act damn
16 sick -- who have a bacteremia who have low total white
17 counts, yes.

18 Q. Well, isn't it with meningococcal bacteremia
19 that if it's fulminant you can have one's white cells
20 consumed?

21 A. Well, in any serious infection, white blood
22 cells are consumed, but the body makes up enough new ones
23 so that you have a steady state in the bloodstream,
24 There are situations of fulminant disease in which the
25 destruction of the white cells exceeds the capacity to

1 replace them and the number measured in the bloodstream
2 will, in fact, go down, as it did here.

3 Q. In that instance, you get the shift to the right
4 in the band count, do you not?

5 A. Well, no.

6 Q. I'm sorry. I'm sorry. Shift to the left.
7 Excuse me. Increased neutrophils?

8 A. Well, under those circumstances you would have
9 very few neutrophils of any sort because they are all
10 being destroyed.

11 Q. Okay. Let me ask you this. Do you get a shift
12 to the left with this type of bacteremia¹ infection that
13 Ryan had?

14 A. Well, you can have the presence of immature
15 forms with all kinds of infections, trivial and
16 otherwise. Band counts in this age group are not useful.

17 Q. You saw where he did have a shift to the left?

18 A. Well, he did have 29 percent band forms out of a
19 total of 9,600 total white cells, yes. But as I say, the
20 differential in this age group is not useful.

21 Q. Well, I understand what you're telling me, but
22 let me just ask you this question. If you have an
23 infection or bacteremial infection such as Ryan had, do
24 you get an increase in any neutrophils because they're
25 fighting off the infection -- or attempting to fight off

1 the infection?

2 A. Well, with any infection, you can get an
3 increase in neutrophils. It's not isolated to
4 meningococcal infections.

5 Q Does Ryan have a shift in his right?

6 A. No. If you look at his differential count, the
7 common interpretation of that would be a shift to the
8 left.

9 Q. As to viral infections, don't you more likely
10 than not expect the shift to be to the right rather than
11 the left?

12 A. Again, in this age group, the differential count
13 does not help you with regards to viral or bacterial
14 infections.

15 Q. Well, if you do have a viral infection, do you
16 normally see a shift to the right as opposed to the left?

17 A. No, not necessarily. That's why it's not a
18 useful tool. And, in fact, if you look at the Baraff
19 article, they specifically tell you not to use the
20 differential counts because it is not a useful tool,

21 (The deposition recessed at 4:00 p.m. and
22 resumed at 4:05 p.m. as follows:)

23 Q. In looking at Mrs. MacAdams' deposition, the
24 portions you've highlighted, there's a series of
25 questions in here regarding the rash that Mrs. MacAdams

1 testified about. What was the significance of that to
2 you? Why did you highlight it?

3 A. Well, as you've already pinpointed through your
4 own questioning, I was concerned about the fact of the
5 rash and whether it were present, and if so, what type of
6 rash it was, and so on, and she was, of course, one of
7 the main people who is involved in the memories of those
8 things, so I highlighted information regarding the rash
9 from her deposition. With Dr. Poleyndard, it was easy
10 because he doesn't recall seeing the rash.

11 And then I highlighted references to the rash in
12 the medical records in order to formulate in my own mind
13 whether I thought a rash were present, and if so, what
14 kind it was.

15 Q. Okay. And if the rash was present as described
16 by Mrs. MacAdams, how would you categorize that type of
17 rash?

18 A. Well, she says that she has a memory of not only
19 the rash being there on the chest, but of it being a
20 small pinpoint rash. And when Dr. Poleyndard looked at
21 the rash and pressed on the rash, the color did not press
22 out of the rash; therefore, it was a nonblanching rash.
23 So if you only look at her memory alone, it would be
24 classified as a petechial rash on the chest.

25 Q. Let me see if there's anything else while on

this particular subject.

you also had some squiggly lines by the question regarding had his muscle tone changed, and according to Mrs. MacAdams, he was more listless and more subdued. Did that have any significance to you and your opinions in this case?

A. Well, the information was relevant to me because it seemed to me that Dr. Poleyndard was obliged to be sure that the child he was sending home was not a sick child. He was not the admitting emergency room physician, but he was the discharging emergency room physician. He did say that he went in and examined the child, reexamined the child, and the other reasons that he came in to see the child

What I wanted to do was to gather information as to what the child was likely to have looked like at the time that the decision was made to finally send him home, and hers is, of course,, one of the important memories.

Q. If you assume her recollection to be correct, would you agree with me that Dr. Poleyndard violated the standard of care generally employed in the medical profession in discharging Ryan without further workup in reevaluation and holding him there?

A. No, not necessarily. The words that she was using -- and of course, so much depends on words here --

1 were a mixture of observations that suggested to me that
2 the child was not as active as normally he is, and was
3 quieter than normal, But based on the words that she
4 spoke, at least in her deposition, and only looking at
5 those alone, I did not get the impression that this was a
toxic or damn sick child.

7 Just to finish my sentence, under those
8 circumstances, it would have been acceptable for
9 Dr. Poleyhard to send home a child who was not looking
10 toxic, given the fact of the other reassuring aspects of
11 the child's evaluation in the emergency department,
12 including the long period of observation, the reassuring
13 total white count, and the fact that the parents seemed
14 capable of reporting back any changes.

15 Q. Well, that white blood count -- you called it
16 reassuring white blood count -- could that white blood
17 count be one that was falling --

18 A. Well --

19 Q. -- based on knowing what his disease process was
20 later on?

21 A. Well, again, I have to look from the standard of
22 care perspective. I have to look at it from that
23 perspective. I can't hold Dr. Poleyhard responsible for
24 not seeing the future, If I knew I was going to have a
25 heart attack next week, I would check into the hospital

today

All you have is what you have at the time. Consequently, he sees a child who has a total count of 9,600. Now, that's a reassuring white count. It's the kind of white count that decreases the perceived risk of a serious illness. Not down to zero, but down to a lower level than when you first started off.

Plus, you have a child who's been there for three hours and has three hours' worth of intermittent observations. And if, in his opinion, the child was not becoming sicker while in the hospital, those are all reassuring elements that lead to an acceptable decision to send the child home.

Q. If you evaluate a child, do you make documentation of that evaluation?

A. I don't understand the question, because there are many points of evaluation of a child.

Q. Well, if Dr. Poleyhard testified that he evaluated this child and did an examination of the child in his deposition -- Do you remember reading that?

A. Yes.

Q. And if he did that, do you agree with me that the standard of care requires documentation of those findings about the examining physician?

A. No, I've never thought that the level of

1 documentation and the standard of care were the same
2 thing. I believe they're two entirely different things.

3 Q. Well, do you document if you would have examined
4 this child?

5 A. I think it depends on the clinical setting, but
6 if the child is really unchanged, there would be no
7 reason to document based on -- For the child's sake,
8 there would be no reason to document a child who has
9 exactly the same constellation of physical findings at a
10 later stage that they did at an earlier stage.

11 Q. Well, that's your determination that there was
12 no change in condition.

13 MR. MULLER: Which is what Poleyhard has
14 testified to.

15 Q. Well --

16 A. My understanding of reading his deposition,
17 sir -- and all I have are the depositions --

18 Q. Right.

19 A -- is that he claims that if there would have
20 been a meaningful change, he would have documented it and
21 presumably even acted differently. And I must say, it is
22 the convention in medicine that things that are not
23 written down are taken to be normal or unchanged or
24 whatever the case may be. So the lack of any written
25 summary of the reexamination on the emergency room sheet

1 is not unusual, in my experience.

2 Q. You would agree with me that the onset of Ryan's
3 symptoms were sudden, according to the family, before
4 they arrived at the emergency room, on the triage note?

5 MR. MULLER: You mean the parents have said on
6 the triage note that they were sudden?

7 MR. BERGEN: No.

8 Q. According to the notes, it gives a complete
9 complaint and history of sudden onset of expiratory
10 grunting, tense, nausea, elevated temperature, began
11 approximately one hour ago, 4:30 p.m. You're aware of
12 that?

13 A. Yes.

14 Q. That would be a sudden onset by history, would
15 it not, of temperature? Expiratory grunting?

16 A. You used the word "sudden." If someone has got
17 a fever, it's got to begin sometime.

18 Q. It's not chronic?

19 A. At that moment is onset. To call that sudden is
20 really no different than any febrile child. Fever in a
21 child must begin at a certain point.

22 Q. You've seen different studies that talk about
23 chronic fevers over two weeks of age, sudden onset, or
24 acute fevers?

25 A. Oh, I would call this an acute febrile illness,

1 but the characterization of this as being a sudden
2 illness -- fever must begin at a certain point.

3 Q. Okay. Do you practice emergency room medicine?

4 A. Let me answer that in two ways. The answer is
5 yes in the sense that I see patients in the emergency
6 room, but only pediatric. I don't do adult emergency
7 room work. And I'm called in to consult on patients in
8 the emergency room. But -- if I could just finish --
9 this particular kind of illness that this child has is
10 bread-and-butter pediatrics that occurs in offices,
11 clinics, and emergency rooms, and it's not
12 quintessentially an emergency room issue the way an
13 automobile accident would be.

14 Q. Well, I mean, do you see patients -- I say -- I
15 don't want to take this literally. Do you work emergency
16 room shifts?

17 A. No, I do not, but our emergency room is situated
18 in a way that they can just call me when a patient
19 arrives if it's a patient that, for example, I've brought
20 in to be seen or that they want me to see.

21 Q. Is that by consult?

22 A. No. There are children that I will see
23 primarily in the emergency room, but also I will be asked
24 to come in to see children that have been already
25 evaluated by an emergency room doctor. We do it all ways

at our place,

Q. What I'm trying to get at, when I think about an emergency room physician, I'm thinking of the front-line emergency room physician who takes all kinds. You don't work that kind --

A. No. I don't see adults. I see only pediatric patients.

Q. When you see a pediatric patient, if you see a pediatric patient in the emergency room, it's at the request of the emergency room physician?

A. Sometimes it is, but sometimes I will see the child as the primary physician.

Q. You say, "Meet me in the emergency room," and you see the patient there?

A. Yeah, either I will, or the nurse who takes the telephone call will say, "Call to the emergency room and ask for the pediatrician," and I'm the poor old pediatrician who sees that child.

Q. Did the fact that Ryan had been irritable 15 minutes prior to arrival, by crying, have any significance to you in formulating your opinions as to whether or not further workup should have been done on Ryan during the first emergency room admission?

A. All historical elements have importance, but that fact in and of itself I don't believe would alter my

opinion that the correct workup was, in fact, given to
2 the child

3 Q. Okay. If Mrs. MacAdams asked Dr. Poleyndard to
4 look at the rash that she described on Ryan in her
5 deposition, would you have expected Dr. Poleyndard to make
6 a note entry about that rash or not?

7 A. Not necessarily.

8 Q. Did the standard of care require for the
9 differential to come back and be reviewed before
10 discharge on Ryan?

11 A. You mean the differential white count?

12 Q. Yes.

13 A. No, because as I've said, in the age group, the
14 differential count is not of importance in making a
15 medical decision as to what to do with the child, as is
16 clearly stated in the Baraff article.

17 Q. Then why would you order it?

18 A. I don't.

19 Q. In this case it was ordered.

20 A. It was.

21 Q. Do you see any reason why it should have been
22 ordered in this case?

23 A. Well, I don't know what their normal routine is,
24 sir, in this emergency department. There are many
25 emergency departments that I know of, including ours. In

some of them, it goes together like peanut butt and
2 jelly. You order a white count; you get a differential.
3 Consequently, you don't have the option of ordering only
4 one or the other.

5 In our clinic, however, it's different. We can
6 order either a general hemogram that only has the total
7 white count or a differential. But in the emergency
8 department, it's done, I think, as a matter of course. I
9 don't know whether this was a conscious decision that was
10 made by Dr. Perez to order the differential or whether
11 it's just what we do in our emergency department.

12 Q. Okay. And as to the temperature of this child,
13 the 104.3, was enough to be done in this case to meet the
14 standard of care Just one temperature on admission and
15 that's it?

16 A. That's correct, because, you see, fever's only
17 useful as a stop sign to tell you to look at the child,
18 that this child has a febrile illness and needs an
19 evaluation. Further measurement of the temperature is
20 not useful from a diagnostic point of view.

21 And, in fact, I must say in all honesty, we have
22 in pediatrics a condition that has been called fever
23 phobia, where parents become quite apprehensive when they
24 have fever alone, as if fever was going to harm the
25 child. And we feel in our department that fixation on a

1 temperature level for no good reason just reinforces that
2 in the family.

3 Q. As to what's in the chart, I take it that you
4 considered everything in the chart on the first emergency
5 room admission to be accurate and correct?

6 MR. MULLER: I'm sorry, what was that question
7 again?

8 Q. You considered everything in the chart as being
9 accurate, did you not?

10 A. I didn't see any contradictions that would have
11 made me suspect that it was inaccurate.

12 Q. Okay. Now, you've also been provided opinions
13 regarding Ryan's prognosis. Let's see. We'll mark this
14 as an exhibit. The interrogatory responses you've given
15 us about your opinions is that you expect to testify to
16 the issue of standard of care and caution based upon
17 various facts which have been presented in the medical
18 records and depositions, and based upon test results,
19 that Dr. Poleyndard acted within the standard of care in
20 his diagnosis, treatment, and discharge of Ryan MacAdams.

21 I think we've covered that aspect of your
22 opinions, have we not, in its entirety, or is there
23 anything else that you need to add that supports, in your
24 mind, that Dr. Poleyndard acted in the standard of care in
25 discharging Ryan?

1 A. Well, just by way of summary, I believe that
2 Dr. Poleyndard did in fact re-examine the child, did not
3 find a child who had a meaningful deterioration from when
4 he was seen by Dr. Perez, did not find a child who was
5 toxic who needed a more comprehensive reevaluation or
6 alternate management plan.

7 I do not believe that a rash was present, but if
8 it were present, I believe that Dr. Poleyndard did, in
9 fact, look at it and made a judgment in his mind that
10 this did not alter the acceptability of sending him home.
11 And I believe that he provided good follow-up information
12 and instructions for the family. So under those
13 situations, I believe he met the standard of care.

14 Q. Okay. Even if a petechial rash was present on
15 Ryan, he met the standard of care, is what you're telling
16 us, too?

17 A. If the child had a petechial rash but was a
18 nontoxic child -- which I'm not admitting was the case.
19 This is a hypothetical situation -- I believe under the
20 circumstances that it was an acceptable treatment option
21 to send the child home with close follow-up if the child
22 were, in fact, nontoxic, as I state that I believe the
23 child was.

24 Q. And when you say "nontoxic," you just said that
25 you think the child doesn't look sick?

1 A. Exactly, does not have a global appearance of a
2 child who is seriously ill.

3 Q. Okay.

4 A. Remember, Dr. Perez was quite eloquent in what
5 he wrote down in making a description of the child.
6 Consolable, alert, tracking, appropriate response,
7 et cetera. If the child did, in fact, have those things
8 at the time that he was being discharged or did not have
9 a meaningful alteration from that state, that is a
10 nontoxic child,

11 Q. But if the child did have a toxic appearance
12 with petechiae rash, then the child should not have been
13 discharged?

14 A. I agree.

15 MR. MULLER: As defined by Dr. Radetsky on what
16 a toxic-appearing child is.

17 MR. BERGEN: Right.

18 A. Right, using my own concept of toxic.

19 Q. Which I still don't have a good feel for except
20 it's just the child looks sick, is what you're telling
21 me?

22 A. Well, it's not just that, sir. It's one of
23 those terms which is inexact to people who don't see
24 children as a care provider day in and day out. But for
25 someone who's in the business, when you say "toxic" or

"looks and acts damn sick" or "child looks seriously ill," you know what you're talking about.

There has been extensive investigation in trying to come up with other words for these things and also to come up with a profile. One of the most famous of them was done in the early 1980s at Yale by Dr. Paul McCarthy, and it's called the Yale Observation Scale, and it looks at the child's color, sociability, state of hydration, consolability, breathing pattern, and the like in order to define toxic, as well.

But I must tell you, despite the fact that it's been used as a research tool, the Yale Observation Scale has never come into general use, and what has remained is this concept that in looking at a child who looks inappropriately ill for a -- as a constellation of features, of their alertness, their interactiveness, their sociability, their color, their breathing, their activity, their body tone, and the like, and you must understand it's very age-specific, then that child is nontoxic.

If a child, however, you know, is withdrawn, flaccid, mottled, breathing rapidly and heavily, has cool extremities and so on, then you consider that child probably to be a toxic child. It means something to people who actually do the work.

1 Q. What about the fact that there is a history of
2 this child grunting? Doesn't that cause some kind of
3 concern for respiratory compromise?

4 A. The initial reporting of that historical fact
5 does, but it was not confirmed by the subsequent
6 examinations of the child in the emergency room
7 department. And I believe the mother has testified that
8 it was not present in the emergency department.

9 Q. But the history would be of some importance to
10 you?

11 A. It would be of importance, but unless it were
12 validated by a finding at the time of examination, it
13 probably could be discounted since serious things that
14 cause grunting do not go away.

15 Q. In reading about toxic appearances, I've come
16 across the word "listlessness." Is that one of the
17 things that is equated to one of the clinical symptoms of
18 toxic? "Listless child," I think it's been referred to.

19 A. Yes, "listless" is another one of those words
20 for which there is no good definition. "Lethargic" is
21 another one. That's why you really have to get a better
22 description of what the child is or is not doing in order
23 to make an independent assessment, and that's why in
24 reading the mother's deposition it's a little bit
25 difficult to know what she thought of her child, because

she uses so many different words to describe the child including "somewhat subdued," which is -- again, it's only a word, but it conveys a different feeling than a child who is, perhaps, listless or a child who's lethargic.

Words mean what the people say that they mean, to tell you the truth. And in looking at the chart at the time, it is my judgment that to the examiners at the time, the child did not look and act seriously ill, and I cannot find a contradiction to that in the mother's deposition.

Q. So even when she says that the child was lethargic, you rule that out?

MR, MULLER: Mom never said that,

A. I didn't see that in her deposition. I saw "somewhat subdued"; I saw the word "listless." I'm trying to think of some of the other words that I saw in there. But I never saw "lethargic." So, again, I'll have to confront that word. But that's another one of those words that means different things to different people. I have nurses who come in and say they feel really lethargic.

Q. What does lethargic mean for an infant?

A. I try not to use the word because it doesn't have a common definition. That's why I will write down

words that mean something to me A child that is tracking, a child who's consolable, a child who's alert, these things mean something to me.

Q. Do you know if he actually wrote those down or those were complete sentences made by the Carswell dictation system that was being used at the emergency room?

A. I knew that they had a dictation system. I was unfamiliar with the fact that it generates its own words, And if so, I'll need more information as to what you key in. But I presume that -- Dr. Perez seems to support that in his deposition, that these words accurately described the child. He was accurately describing the child he was seeing.

Q. What does "subdued" mean to you, if a child is subdued?

A. I think it means to me that the child is just a little bit less interactive than usual, less interested in social overtures than usual, a little bit more quiet than usual, a little less demonstrative than usual. Mind you, we're getting on to 7:00 and 8:00 at night, and a child with a fever being a little less than **all** of those things does not seem to me to be out of the question for a four-month old child.

Q. Is there anything else that you base your

opinion that this child -- that it was acceptable to discharge this child that you haven't --

A. I think we've talked about all those things. And again, I think that the follow-up information presented in written form during the time of the reevaluation in the emergency department and the hospitalizations supports my conclusion that, more likely than not, a rash was not present.

Q. What do you base that on?

A. Well, there are a number of references in the subsequent chart. There, for example, is the reference in the chart that Dr. Poleyndard fills out at the second admission that states the child developed a petechial rash. So that would have occurred after the child had been sent home. Then there are a number of references by physicians and nurses in the Memorial Medical Center notes that, with only one exception, all refer to the rash developing after the time of the emergency department visit.

Q. And what exception are you referring to?

A. The only exception is a note that is written on this sheet called Nursing Progress Note.

Q. Right.

A. And it's 5:30 a.m. to 6:20 a.m. -- and I can't read the handwriting, so I don't know who wrote it -- and

1 it refers to the following statement by the mother. "Mom
2 states that baby was treated for viral illness and
3 released. Also, mom noted (quote) petechial rash to
4 abdomen which did not impress M.D.'s at St. Joseph's."
5 And there's no other quotation marks, so I don't know
6 whether that ends. That's the only deviation from what I
7 see as a consistent recording of the rash occurring after
8 the emergency department visit in multiple places in the
9 hand of various other individuals.

10 Q. So that's the only exception that you noted?

11 A. That's correct.

12 Q. But, I mean, obviously, for some reason, you
13 went through the medical records carefully and were
14 noting the rash. You were concerned about the rash
15 because you know that's a red flag in this type of
16 treatment of these patients, right?

17 A. I needed to know the facts before expressing an
18 opinion, and I tried my best to get at them.

19 Q. If a rash was present, would that change your
20 opinions?

21 A. I think that any new physical finding that was
22 not claimed to have been seen by the examining doctors
23 would have to go into my opinions, so, of course, I was
24 concerned about that, as well as any new physical finding
25 that might have been there.

1 Q. But you knew the rash was an important finding
2 in this type of disease process?

3 A. In retrospect, yes.

4 Q. Well, you would know that, if you were treating
5 a patient, a new rash has an important consequence in
6 this type of infection?

7 A. All rashes are important in that child with a
8 fever because they may be a clue to the cause of the
9 fever.

10 Q. Now, the next point on the interrogatory answers
11 states, "On the matter of causation, Dr. Radetsky is
12 expected to testify that there was no causal connection
13 between Ryan MacAdams not being diagnosed with
14 meningococcal infection or treated with antibiotics
15 during his first ER (admission), and his development of
16 orthopedic and other problems. Treatment with
17 antibiotics during the first (admission) would not have
18 prevented such problems. Also, it is likely that the
19 orthopedic problems were unrelated to the meningococcal
20 infection."

21 I take it -- Let's do this, Let's take that in
22 subsections, if we can.

23 A. Sure.

24 Q. If Ryan had had a blood culture done during the
25 first admission, more likely than not it would have shown

meningococcal infection -- Neisseria -- You have to --

A. Just call it the meningococcus. It's a lot easier.

I believe more likely than not that that is true.

Q. And with that in hand, standard of care requires immediate antibiotic therapy?

MR. MULLER: You mean when the blood culture finally comes back?

Q. Well, if you suspected it beforehand. But you could start antibiotics even before *you* got the result back, right?

MR. MULLER: Well, now you're skipping around. you're talking --

MR. BERGEN: Peter, just calm down. I'm asking a good question.

Q. You testified that if -- or you've purported to testify that if he was treated with antibiotics at the first ER admission, it wouldn't have made a difference with any of the development of orthopedic or other problems.

A. That is correct.

Q. That's where I'm trying to get to. Tell me what's the basis of that opinion.

A. Sure. If his bone injuries and his injury to

1 bone growth were caused by the meningococcus, as I think
2 it could have been caused -- and there are four articles
3 in my packet that someday you'll get that have to do with
4 this -- it is an extremely rare complication of
5 meningococemia.

6 And the reason I say it's extremely rare is that
7 in the best of those articles published from Baltimore by
8 the University of Maryland Group, they can only come up
9 with somewhere between 12 and 21 cases of this ever being
10 reported in the literature. They refer to 12, then they
11 mention an article in which 9 more cases could have been
12 due to meningococemia, but they didn't do all the
13 cultures to find out one way or the other.

14 But at any rate, that's an extremely small
15 number of cases in a disease which is not that uncommon.
16 Thousands of cases a year occur of meningococcal
17 infection in the United States alone, much less the
18 world. That's an extremely rare complication,
19 Consequently, we're dealing with a serious illness that's
20 not uncommon, but not terribly common, and an extremely
21 rare complication of that illness. Consequently, there
22 is absolutely no information regarding duration of
23 illness, timing of antibiotic therapy in meningococcal
24 infection and the risk of full-blown disease. There's
25 just no information on that at all and no one possesses

1 that information because it's so rare.

2 Consequently, you have to look at the
3 relationship between the timing of therapy in the context
4 of illness and outcome in other areas of meningococcal
5 infection to try to come up with biological principles
6 you can apply to this case.

Are you with me so far?

7 1 Q. Somewhat. Do you see anything in all the
8 medical records you've reviewed that would explain any
9 other cause, other than the meningococcal disease, to
10 Ryan's infarcts?
11

12 A. I'm not an orthopedic surgeon, and I don't
13 pretend to be an orthopedic surgeon. I believe the
14 meningococcal infection could have caused those bony
15 infarcts, but there are many other cases that I'm
16 unaware. And, of course, the treating doctors who are
17 dealing with his bones, they don't care what the original
18 cause might have been. They're just trying to deal with
19 the cause that he has these growth arrests on these
20 various long bones.

21 Q. Do you think the people treating his condition
22 now are less qualified to express opinions as to the
23 origin of the bone infarcts?

24 A. Less qualified than what?

25 Q. Than you,

1 I don't believe they're less qualified than me
2 no.

3 Q. Are they more qualified than you?

4 A. They might be. I don't really know any of the
5 people who are treating him, so I can't really answer.

6 Q. But, I mean, you aren't ruling out that the bone
7 infarcts was caused by the disease that he had?

8 A. I'm not ruling it out, sir. I just think it's
9 an awfully rare complication and, therefore, there may be
10 some other condition that causes this. I just don't
11 know.

12 Q. Do you have any other explanation as to what
13 caused these bone infarcts?

14 A. I honestly don't, because I'm not an orthopedic
15 surgeon, and it's not an area in which I express any
16 expertise.

17 Q. And the articles -- and I haven't reviewed the
18 ones that you have here today -- do they associate the
19 bone infarcts with the **DIC**?

20 A. They do.

21 Q. Could one possible explanation be, as to why you
22 have not seen as many case reports of bone infarcts, is
23 because, A, generally this disease progresses to
24 amputation from necrosis and gangrene; and, B, death?

25 A. well, I think you raise an important point, In

1 purpura fulminans, which this child had, the combination
2 of shock, DIC, and purpura in meningococcal disease,
3 there is a considerable death rate and there is a
4 substantial risk of loss of some portion of the body,
5 whether it's a digit or a limb or something of this sort.

6 But the answer is no, I don't believe that that
7 fact alone would deprive the world of medical literature
8 of a number of case reports of this delayed diagnosis of
9 bony infarcts or growth plate arrests in meningococcal
10 infection if it were a common occurrence, no. The
11 answer's no.

12 So the fact that the best of all articles can
13 only report a handful of cases implies that it must be a
14 rare complication, because there are articles -- and I
15 supplied one of them to you -- about purpura fulminans,
16 just in -- just from one measly institution that's
17 recording or reporting scores of cases of purpura
18 fulminans in meningococcal infection. So clearly it must
19 be much more uncommon. So this is a rare condition. And
20 I've never seen one in my lifetime, and I've seen
21 hundreds of cases of meningococcal infection.

22 Q. Has antibiotic therapy been effective in the
23 cases that you've treated?

24 A. What do you mean, "effective"?

25 Q. I mean successful, retarded any long-term

1 sequelae.

2 A. Well, in the cases that I've seen, I've seen a
3 spectrum of outcome.

4 Q. I'm talking about the cases you've been actually
5 hands-on, not what you've consulted.

6 A. I understand. In the cases I've seen, I've seen
7 the gamut of outcomes, including death, limb
8 dismemberment, burn-like injuries in the skin because of
9 large amounts of skin loss, meningitis, organ
10 infarctions, or total survival without any problems
11 whatsoever. So I've really seen the gamut.

12 Q. Do you believe that timing of antibiotic therapy
13 is important to retard meningococcal CB?

14 A. I think that the timing of antibiotics does not
15 influence many of the more serious outcomes of
16 meningococcal infection; that the timing of
17 antibiotics -- Clearly, you're worse off without
18 antibiotics than you are with antibiotics. But in terms
19 of the sensitivity of outcome to the timing of
20 antibiotics, I believe that there is a general grace
21 period within which the timing of the antibiotics leads
22 to an equivalent outcome.

23 Q. Okay. And you've criticized studies that have
24 promulgated -- you know, in your writings -- timing of
25 antibiotic therapy having a better outcome. The earlier

1 the treatment, the better the outcome.

2 A. What I have criticized is unsubstantiated
3 claims.

4 Q. Right, scientific proof.

5 A. Yes. In other words, it is an old saying that
6 the earlier you treat, the better off you are. And in
7 general that is true, but what it ignores is the fact
8 that there are certain conditions in which antibiotic
9 therapy is helpless to prevent death or severe outcome.
10 And in general, there is a wide grace period within which
11 timing leads to an equivalent outcome.

12 So what I complained about is the fact that
13 people say this phrase or make this statement when the
14 truth is more complex than that, and they say it in an
15 unsubstantiated way.

16 Q. Isn't it true that there's no scientific proof
17 due to the fact that you don't hold off antibiotic
18 therapies with patients like Ryan if you know that that's
19 what they have? You can't do a study on them because
20 then you're doing it to the detriment of the patient?

21 A. That's correct, you can't do a prospective
22 randomized trial in which one of the choices is not
23 giving antibiotics.

24 Q. Right, like giving one antibiotics and giving
25 another a placebo?

1 A. That's correct. So what you have to do is get
2 at information some other way.

3 Q. What? What other ways have you read or
4 learned -- That's probably a bad word to use. Are you
5 familiar with the increased LPS's in individuals with
6 meningococcal disease or with high levels associated with
7 worst prognosis?

8 A. Yes, it is true that the worst prognosis is
9 associated with increased levels of endotoxin, or LPS as
10 you've expressed it, in the bloodstream. That is a bad
11 prognostic sign in those studies that actually looked at
12 it. And there haven't been that many studies, but there
13 have been some.

14 Q. Have there been studies that look at early
15 administration of antibiotics and that prove the level of
16 LPS falls, and prove that antibiotic therapy does make
17 them fall in meningococcal disease?

18 A. Actually, there have been two sets of studies.
19 One set of studies showed that there was a spike in the
20 level of LPS or endotoxin in the serum right after they
21 gave the antibiotic. In other words, there was more
22 present. And then there are other studies that show that
23 after you get the antibiotics, you will, in fact, then
24 see at a certain point a decay in the amount of LPS that
25 you measure in the serum.

1 Q. You've read studies where the conclusion was
2 reached that because you give antibiotic therapy and the
3 LPS falls, then, therefore, antibiotic therapy does help
4 meningococcal disease?

5 A. I have seen that claim in the study that --
6 Again, there have only been a few studies of these sorts,
7 anyway, that saw the decline in LPS levels. The trouble
8 with that is that the bad outcome in meningococcal
9 disease has more to do with the host than it does with
10 the level of the LPS.

11 Q. And that's kind of where you've written or
12 you've promulgated that this is the host response, not
13 the timing of the antibiotic therapy?

14 A. That's correct. The timing of antibiotic
15 therapy doesn't alter the host response, so that if you
16 have a host that responds in a particular malignant way,
17 injuring its own body in the process of fighting the
18 infection, the antibiotics don't seem to help that kind
19 of person as much as they would help, for example, a
20 person who can kind of respond in a more modulated
21 manner, and under those circumstances long delays in
22 withholding antibiotics could lead to a deleterious
23 outcome.

24 Q. You would agree with me that since the advent or
25 inception of antibiotic therapy in treating

1 meningococemia, that the mortality rate has decreased
2 from greater than 80 percent to less than 20 percent?

3 A. That is correct.

4 Q. And talking about the host response concept that
5 you espoused, that if you have less than 20 white blood
6 cells in the CSF fluid, that is a prognosticator that the
7 host -- there's a failure of the host neutrophils to
8 mount an appropriate response?

9 A. The usual viewpoint on these matters is that if
10 an individual with meningococcal infection has
11 meningitis -- meaning greater than 10 or 20 white
12 cells -- it's thought to be a good prognostic sign
13 because it means that their body has been able to control
14 the disease long enough for them to develop the
15 meningitis. That has actually been looked at now a
16 second time around, and the most recent studies do not
17 show that the presence of meningitis puts the individual
18 in a better prognosis category, so there now seems to be
19 some disagreement amongst investigators regarding this
20 issue.

21 Q. Okay. But as to the white blood cells in the
22 CSF fluid, are you familiar with any literature or
23 studies that give an account --

24 A. Well --

25 Q. -- that are significant? Regardless of the

1 meningitis?

2 A. If you have a small number of white blood cells
3 in the CSF, people oftentimes interpret that as not
4 having meningitis. So I would actually have to look at
5 the study to know how they made the diagnosis of
6 meningitis but with no white cells in the spinal fluid.

7 Q. But you have to have -- explain to me -- In
8 order to have white blood cells in the CSF, you have
9 meningitis?

10 A. That's correct.

11 Q. And the finding of meningitis in the CSF or not
12 now is thought not to be a good indicator or a bad
13 indicator of outcome?

14 A. That's correct. The most recent studies to look
15 at it do not find that the presence or absence of
16 meningitis can give you a prediction of how well or
17 poorly the person will do.

18 Q. Okay. Did you make a determination as to
19 whether Ryan had meningitis in his blood count --

20 A. Yes.

21 Q. -- or CSF?

22 A. Yes, I did make that determination.

23 Q. What was your determination?

24 A. He did have meningitis.

25 Q. And did you look at the white blood cells?

1 A. Yes. He had a spinal fluid that showed 48 white
2 blood cells.

3 Q. And wouldn't that be an indication that the host
4 neutrophils -- there was not a failure of the host
5 neutrophils to fight off or appropriately respond if
6 earlier intervention had been instituted in this case?

7 A. Well, I'm sorry, but the problem with this child
8 was not a neutrophil problem. The problem with this
9 child was the blood vessel disease. And under those
10 circumstances, the level of neutrophils is a very poor
11 guide.

12 Q. I'm going back. If antibiotic therapy had been
13 introduced initially, not later. The first admission.

14 A. Then I'm confused as to the role of neutrophils
15 in your inquiry,

16 Q. Okay. So the fact that he had 48 white blood
17 cells in the CSF is not -- does it weigh in your opinion
18 one way or the other?

19 A. That's correct.

20 Q. And the fact that he had meningitis was
21 originally thought would be a good prognosticator of
22 earlier antibiotic therapy, better outcome?

23 A. Well, no, it's not a prognosticator that early
24 antibiotic therapy should or shouldn't have been given in
25 that sense. Just taken as a prognosticator, it has been

1 thought in the past that the presence of meningitis was a
2 good prognosticator. More recent studies looking at it
3 could not confirm that.

4 Q. Okay. Do you differ with the earlier studies,
5 or where do you line up on that school of thought?

6 A. School of thought. It's been my experience that
7 meningococcal disease is not good no matter what you have
8 in the way of spinal fluid findings. I've seen
9 individuals develop malignant brain swelling with
10 meningococcal disease and die because of the meningitis,
11 so I'm not convinced that the presence or the absence of
12 meningitis is of any clinical use at all.

13 Q. When you mentioned earlier about endotoxins, is
14 that the real culprit in this disease?

15 A. Which, sir?

16 Q. The real culprit to causing injury and death is
17 the release of endotoxins in the cell wall?

18 A. Well, the real culprit in this disease is the
19 way that the child reacted to the presence of the
20 meningococcus. You see, this was a serotype B
21 meningococcus. It's actually a less virulent form than
22 other forms of meningococcal infections, particularly the
23 serotype C, which is seen now commonly in the United
24 States, which has worse outcomes in general,

25 The real problem here was this child had zero

1 blood vessels reactivity, a severe vasculitis. It
2 certainly was started by the presence of the
3 meningococcus -- no question about that -- but took on a
4 life of its own that continued despite the fact that you
5 killed off the meningococcus. And therein lies the
6 difficulty of ascribing tremendous advantages to the
7 timing of antibiotics in a disease in which it is the
8 host blood vessel injury and excessive clotting of blood
9 vessels which led to the DIC, purpura fulminans, and
10 possibly the bone injuries in this child, which is not
11 subject to modification with antibiotics.

12 Q. Let's back up, if you don't mind, to help me
13 understand that. You're saying that he had the type B,
14 which is usually not as strong as other types of
15 meningococemia?

16 A. That's correct. The serogroup B meningococcus
17 is a less virile type organism than other serotypes.

18 Q. Now, what you're telling me, then, I take it is
19 because he had -- he was not able to fight off DIC --

20 A. No, what I'm saying is that DIC and the purpura
21 fulminans that this child has is not the result of a
22 poison excreted by the germ or a destruction of blood
23 vessels because of the infection. It is the result of
24 his reaction to the infection. And he reacted to the
25 infection with inflammation in the small blood vessels as

1 well as clotting within these damaged vessels, and it is
2 this kind of reaction that he had that led to all of the
3 subsequent problems that he encountered both with regards
4 to the initial management at Memorial Hospital -- which I
5 think they did a fine job of -- his kidney failure, the
6 need for blood products, and attempts to slow down the
7 DIC, and then ultimately the skin disease, and perhaps
8 even the bone disease if, in fact, his bone disease was
9 due to the meningococcus.

10 Q. When do you think the window of opportunity
11 closed on this child to stop that type of reaction?

12 A. I honestly believe, sir, that once the infection
13 gets established in a patient who's going to react that
14 way, that antibiotics don't alter the process. In other
15 words, to restate it, from the time that one could have
16 reasonably made the diagnosis and reasonably instituted
17 therapy, the die is cast if someone is going to react
18 this way.

19 Q. When do you think, then, infection was
20 established with Ryan?

21 A. I just have no idea, and no one really can know.
22 That's an impossible task to know when the first germ
23 arrives or, you know, when it first gets into the
24 bloodstream. These are imponderables that no one can
25 know.

2 You agree that meningococcus is a very rapidly
dividing organism?

3 A. It divides as rapidly as any other organism,
4 sir.

5 Q. Does it divide every thirty minutes?

6 A. No one knows actually the division rate in the
7 human body. In a laboratory beaker of growth broth with
8 no defenses, it probably divides every 30 to 40 minutes
9 depending on the temperature and the nutrients
10 Meningococcus needs particular nutrients.

11 But, you see, the body is different. The body
12 has white blood cells, it has a liver and a spleen, it
13 has lymph nodes, it has bone marrow, and it has serum
14 factors which inhibit the growth of bacteria, so that the
15 doubling time in the body is different than the doubling
16 time in a beaker in broth in a laboratory.

17 Q. Have you ever read about where they took --
18 where the endotoxins double every 30 minutes, and if you
19 start one meningococcus at ground zero, in 30 minutes
20 it's one, at an hour it's two, at an hour and a half it's
21 four, and then on out?

22 A. Sure, but this is all done in laboratory
23 beakers, not in the human body.

24 Q. Well, you don't test human bodies in this type
25 of disease because it would be, basically, watching them

1 die before your eyes, wouldn't it, potentially?

2 A. Yeah, you can't get that information from a real
3 human being. Actually, what is known in human beings is
4 that the numbers of organisms usually plateau at a
5 certain level and they do not keep rising until your body
6 becomes clogged up with the organism, so that there is a
7 steady state that is reached, but it's different in
8 different individuals. And this has been done in animal
9 experiments. To put it another way, you can't use
10 doubling times to backtrack to say, "Ah-hah, this is when
11 the disease begins."

12 Q. Right.

13 A. The reason you can't is twofold. One is, you
14 don't really know the doubling time in a particular human
15 body, so you don't know what that number is. And the
16 second is, the disease is not just the organism, it's the
17 response to the organism, and different people respond
18 with different vigor.

19 So someone who responds more quickly, more
20 dramatically, and I might say more malignantly, will
21 actually come down with symptomatic clinical disease
22 earlier in the course of their illness than someone who
23 responds in a very subdued fashion, since the illness is
24 not the organism; the illness is the response.

25 You see, we will treat children who have

1 meningococcal bacteremia that's been untreated for weeks
2 and they just don't respond very violently; consequently,
3 they don't get very sick. They have what's called
4 chronic meningococcemia, which is, if they sampled their
5 blood over one or two or even three weeks, they would
6 remain blood-culture positive, but they wouldn't be
7 terribly ill, They would get rashes that would come and
8 go and fevers that would come and go, but they would not
9 be materially ill. They're not the kind of children that
10 react violently, the way that this fulminant kind does.

11 Q. Isn't it the endotoxins that stimulate the
12 response from the body's immune system?

13 A. It's endotoxins and other parts of the cell wall
14 of the coccus that is the stimulus for these reactions.

15 Q. And with vigorous response from the immune
16 system, such things could be DIC?

17 A. That's one of the ways the body can respond.
18 And, of course, it's not a very intelligent way to
19 respond, since you're harming yourself in response to
20 this organism.

21 And one of the articles that you'll have someday
22 is by Mike Levin, who is a researcher, the professor of
23 pediatrics at St. Mary's Hospital in London, whose area
24 of research is meningococcal disease, and it's a recent
25 study of the state of the art of dealing with these

1 issues. And you can see the perplexity he feels in, one,
2 knowing what actually causes the reaction; two, why
3 certain people react more strongly than others; and,
4 three, what to do about it when you've identified it,
5 because there's just a limited number of means at your
6 disposal to try to deal with it. They did everything
7 they could for this child, but you're limited in what you
8 can do.

9 Q. And from what you've told me, you would agree
10 that the body's response is directly related to the
11 avenue of endotoxins to which the body's exposed?

12 A. No.

13 Q. You would not?

14 A. No.

15 Q. Okay.

16 A. The body's response is in response to the
17 endotoxin, but the timing of the response and the vigor
18 of the response is peculiar to the individual.

19 Q. And in this case what you're telling me is that
20 once the infection was established in Ryan, whenever that
21 was, the die was cast?

22 A. I believe so.

23 Q. Okay. But you can't tell me when the infection
24 was established with Ryan within a reasonable degree of
25 medical certainty?

1 A. Well, I believe he had the bacteremia at the

3 Q. Okay. Was the infection established then?

4 A. Well, I believe it was, because I can't find any
5 other explanation for his fever. Consequently, here's a
6 child who has a fever. It's got to be due to something.
7 We know that just a handful of hours later he has
8 terrible purpura fulminans that anybody could diagnosis.

9 So it's my opinion that when he was being seen
10 on the first emergency room visit, unknown to the
11 treating doctors, who don't have a crystal ball, he had
12 meningococcal bacteremia that was symptomatic, but he
13 hadn't had that violent reaction yet.

14 But even if antibiotics had been indicated at
15 that time -- I do not believe that they were indicated.
16 I do not see an indication for antibiotics, although some
17 people might have given antibiotics because different
18 people have different management styles. Even with that,
19 I don't believe that the process that had begun could
20 have been switched off by the antibiotics.

21 Q. At any time during the first admission?

22 A. That's correct.

23 Q. And do you agree with me that antibiotic therapy
24 can retard the occurrence of DIC in this type -- in a
25 patient with meningococcemia?

1 A. It's very, very hard to answer that question
2 because if you're looking at this very rapid onset
3 disease, I don't believe antibiotics can alter the
4 incidence of DIC. But if you're looking at untreated
5 meningococcal disease before there are antibiotics -- And
6 nowadays with treated meningococcal disease, clearly
7 there are some people who over the course of many days
8 would have developed DIC who aren't going to develop it
9 because they're getting their antibiotics. But that's a
10 different form than an explosive form, this purpura
11 fulminans form. This I don't believe is subject to
12 antibiotics altering the incidence of DIC, particularly
13 if you're dealing here with just a matter of hours.

14 Q. When you say a matter of hours, what do you
15 mean?

16 A. Well, I mean, he's discharged home at 8:15 that
17 night, and he comes back in at 3:30 that morning with an
18 illness that's clear to everybody that he's terribly ill.
19 You're only talking here about seven hours.

20 Q. That's why I wanted to find out what's your
21 understanding when you talk about "a couple."

22 A. I said a handful of hours.

23 Q. Seven hours, 15 minutes?

24 A. But it's not a bunch of days. He's not going
25 two, three, four days without therapy, ill and

1 languishing and deteriorating in front of your eyes.

2 This is a child who only has a fever at this point.

3 On the second visit, he just looks sicker than
4 all get-out. In retrospect, you can't explain his fever
5 at all due to anything else but the meningococcal
6 infection.

7 It does take time to develop the **DIC**. I mean,
8 it doesn't happen instantaneously. But even killing off
9 the bacteria, you know, you've got a spike in the
10 endotoxins when you kill the bacteria. That's going to
11 foment the process that's well in place by seven hours
12 later.

13 I just don't think there's any support to the
14 notion that in this kind of illness that the timing of
15 antibiotics makes a significant difference in outcome.
16 And I think there's good literature support for that
17 contention, and you'll have some graphs to even look at
18 that.

19 Q. In that one case where you did testify on behalf
20 of the plaintiff, would antibiotic therapy have made a
21 difference in that particular case?

22 A. That was a real peculiar case because this was a
23 child who was admitted to the hospital with meningitis
24 caused by H flu, which used to cause most of the
25 meningitis in most cases of the old days, who was put on

1 the wrong antibiotic, and they keep him on the wrong
2 antibiotic, even though he's not getting any better, for
3 ten days. And then he's not better, so they do a spinal
4 tap, and lo and behold, the antibiotic wasn't working.
5 Then he switched the antibiotic, and he has a stroke.
6 That's clearly a different thing. Ten days go by on the
7 wrong antibiotic before you're wise to the fact that it
8 wasn't a wise choice. I think it's different than this
9 situation.

10 Q. Have you testified in cases where there was a
11 12-hour delay?

12 A. Well, as I've already said, I've never testified
13 in a meningococcal case in which I felt that the timing
14 of the antibiotics could have altered the outcome.

15 Q. And of all those cases, what time periods were
16 we talking about? From a range of what to what?

17 A. On which cases?

18 Q. In the cases that you've testified that it would
19 not have made a difference when antibiotic therapy --
20 What I'm trying to find out is what was the delay in
21 treatment ranges in those cases?

22 A. Again, without recalling exactly the cases, my
23 impression is they're all hours, of the same sort as
24 this -- I mean, a handful of hours or a half day or
25 something like that -- in which I felt that the infection

1 was clearly already established, in retrospect. In
2 retrospect. And then by then the process which would
3 have led to the limb injury or the bad outcome had
4 already been started and the momentum was in place such
5 that antibiotics couldn't have altered it.

6 Q. In each of those cases, you're basing that on
7 the individual's response to the disease process?

8 A. Well, I'm basing it on two things. One is what
9 I know about the biology of the disease, which is that
10 the vigor of the reaction is an individual issue,
11 because, clearly, meningococcal infections give you a
12 whole spectrum of illnesses, including some case reports
13 of children who had meningococcal bacteremia who cured
14 themselves, came back in, and they were fine, and you
15 culture them, and it's gone, So it's really a whole
16 spectrum, with a very bad portion of the spectrum on one
17 side, the septic shock, purpura fulminans side of it. So
18 the biology of the disease is one part.

19 But the second part is a series of reports and
20 case series that show that with the disease in general
21 the really bad outcomes seem to be insensitive to the
22 dosing of antibiotics. This means death or severe
23 damage. And, in fact, it's quite clear that from the
24 very beginning, in retrospect, they were kind of set up
25 for these bad outcomes because their disease was very

1 explosive. They were usually sick a very short period of
2 time if petechiae or purpura were present. They were
3 less than 12 hours. They were diagnosed usually very
4 early on because they looked so ill so fast, but they
5 just have that bad outcome.

6 And I've supplied you with some of that stuff in
7 the materials that I had in my folder here.

8 Q. Are you critical of Mrs. MacAdams of how she
9 followed her child that night?

10 A. Oh, gosh, no. You know, she's doing the best
11 she can as a parent, of course.

12 Q. When was the last time you treated a patient
13 with this type of disease that Ryan had? What's your
14 experience per year?

15 A. You mean this spectrum --

16 Q. Yes.

17 A. -- or just meningococcal infection in general?

18 Q. Meningococcal infection in general of an infant.

19 A. Well, just a couple of months ago we had child
20 come into the emergency department who looked well. He
21 was three or four months old. He had a blood culture
22 done, he was sent home. The next day the blood culture
23 was positive for meningococcus. You already know that
24 all the alarm bells went off all over the place.

25 The child was rushed back in. He still had a

1 fever. He didn't look particularly sick. We gave him
2 antibiotics. He was fine. He was obviously a child who
3 didn't react from strictly the meningococcus, because
4 there was 12 or 14 hours between when he was seen and
5 when the blood culture was positive.

6 Q. In that particular case, why did you get a blood
7 consult in the patient?

8 A. I didn't. It was done by the emergency room
9 folks. And I don't know what all went into the decision
10 to get the blood culture. But here, of course, even if a
11 blood culture had been taken, he got ill so fast that the
12 blood culture would not have been read until a number of
13 hours after he was seen the second time around.

14 Q. And in those cases where you suspect and do
15 blood cultures, don't you treat with antibiotics after
16 blood culture immediately?

17 A. No. Most people make those two separate
18 decisions. In other words, the blood culture acts as
19 kind of a fail-safe. Well, I still want to be sure that
20 this child doesn't get out of my hands, so I'll do a
21 blood culture. I don't think he's very sick, so I won't
22 treat him, but I know I have a blood culture present as
23 kind of a -- what's the right word? -- as kind of a
24 safety valve for my concerns because I worry about small
25 concerns, I'm just going through an internal monologue

1 in someone who might order a blood culture.

2 I do it as a safety net for the child. But I
3 really don't think they're ill, so I'm not going to start
4 therapy. Two separate decisions. If I do think you're
5 ill enough to start therapy, I will get a blood culture
6 first. No question about it. But there are often times
7 you get a blood culture even if you don't plan on
8 treating it.

9 I must tell you, with small children who come in
10 with fevers, we often get a blood culture, because if you
11 get a good stick and get a CBC, you might as well get a
12 culture at the same time. Kids being so tough to get a
13 blood culture on.

14 Q. Isn't it true you promulgated the theory of
15 using infants -- of using three different criteria:
16 clinical judgment, total white blood count, and -- you'll
17 have to help me -- erythrocyte sedimentation --

18 A. The SED, or SED rate as we say for short.

19 Q. Yeah.

20 A. I don't think I promulgated that. What I've
21 done, in 1984 I reviewed all the information present up
22 to that time which concerned investigations in the
23 clinical judgment, total white count, and SED rates, and
24 I tried to show clinical judgment is superior to white
25 count and SED rates.

1 And in 1996, I did analysis another way, looking
2 at risks, and I tried to show how you make a judgment
3 sequentially. First you listen to the history, then you
4 get the temperature, then you do your examination, and at
5 each stage you're saying, "All right, now, what do I
6 think?"

7 And then if you're still iffy, you might order a
8 blood count. If you're clear it's not a -- unclear it's
9 a sick child, you may not order a blood count. You're
10 going in stages with a maneuver that you take in order to
11 clarify what you should do next in sequence.

12 Q. Well, in the management of the febrile infant,
13 do you get a SED rate?

14 A. No, I do not. It takes an hour to get back.
15 It's usually not very useful for us.

16 Q. You've written that that doesn't predict the
17 presence of bacteremia, but it rules it out.

18 A. Yes, a normal sedimentation rate decreases the
19 probability of a bacteremia to a very low level, but not
20 zero, obviously, and it can be reassuring if you're kind
21 of on the fence.

22 Q. Did they obtain a SED rate in this case?

23 A. They did not.

24 Q. Are you critical of them not getting a SED rate
25 during the first admission?

1 A. I don't think so. As I said, the white count
2 was normal, the total white count was normal, and that,
3 from their point of view, was reassuring. And they had
4 three hours to observe the child, and I think from
5 Dr. Poleyhard's point of view the child did not look
6 seriously ill after that period of time and, therefore, I
7 don't criticize him for not getting a sedimentation rate,
8 because I don't feel it would have added anything to the
9 management.

10 Q. Would you agree with me that Ryan did sustain
11 serious illness from meningococcal disease in this case?

12 A. Yes.

13 Q. And how would you summarize his injuries as a
14 result of the meningococcal disease? What injuries did
15 he sustain?

16 A. You mean long-term injuries or during?

17 Q. Let's talk about short-term.

18 A. During the acute course, he had a prolonged
19 hospitalization with shock, depression of cardiac output,
20 DIC, significant purpura fulminans, kidney failure, need
21 for artificial ventilation, and meningitis.

22 If you just look at his presentation, his
23 prognosis for death was about 30 percent. So from my
24 point of view, this was extremely good medical management
25 in the acute phase, because he didn't die. I mean -- And

1 he had a pretty awful likelihood of dying. But he had
2
3 long period of time, as you well know.

4 Q. Long-term?

5 A. Well, long-term is as best I can understand it,
6 and I don't have each and every one of his follow-up
7 records, but I do have some. I think that the thing that
8 will affect him the most will be his limb discrepancies
9 and his -- for want of a better word, the malformation of
10 his lower limbs that has resulted from his many surgeries
11 and his growth arrest.

12 And as I said, I think meningococcal infection
13 can cause those bony injuries. I'm not an orthopedic
14 surgeon, and I don't know whether there are a number of
15 other things that can cause it. The treatment I don't
16 think would be any different no matter what the actual
17 cause is.

18 Blessedly, he did not have any brain damage that
19 I can see. His hearing seems to be fine. I note that he
20 had an eye examination done, but I don't believe that
21 they ascribe any eye injury to his meningococcal
22 infection.

23 And then clearly, any child who has any
24 disfiguring injury is going to have an emotional side to
25 that injury, and anyone who takes care of children

1 realizes that and knows that there's going to have to be
2 a good collaboration between the family and the treating
3 health team to try to get him over those emotional
4 hurdles.

5 Q. Do you have any opinion as to how tall he'll
6 ever grow?

7 A. I don't have an opinion. I just don't know.

8 Q. Let's take a short break. I think I may be
9 finished. I just want to check a couple of things, if
10 you don't mind.

11 (The deposition recessed at 5:20 p.m. and
12 resumed at 5:25 p.m. as follows:)

13 (Exhibit 4 marked.)

14 Q. If an infant develops DIC with this type of
15 disease that Ryan had, is it often your opinion that
16 because it goes to DIC, that earlier antibiotic
17 intervention would not have changed the course?

18 A. No, not necessarily. Looking at it in
19 retrospect, because that's the only way I think you can
20 make judgments about matters of causation, he had
21 explosive illness, short period of time of illness,
22 presents with purpura fulminans, develops septic shock,
23 kidney failure, DIC. I mean, that kind of package.
24 Because of his age, it's known that children of this age
25 group typically have worse blood vessel disease and blood

1 vessel clotting and damage to tissue or organs just
2 because of his age. And the reason is that there are a
3 couple of substances in the blood that prevent excessive
4 clotting that are at low levels in four-month old
5 children. Protein C and protein S. Consequently,
6 children of this age in general do worse than adults
7 would with regards to this.

a But it's the explosive nature of this disease,
9 having it so quickly over a short period of time, that
10 makes me feel that by the time he developed a symptomatic
11 illness -- which in retrospect I believe the fever and
12 the illness that brought him into the emergency
13 department was a symptomatic illness -- the portion of
14 his system that reacts to these infections was already
15 geared up and starting to go. It just hadn't quite
16 expressed itself yet.

17 So, even if you killed the germ with an
18 antibiotic, you wouldn't have stopped that. One, it was
19 already in place and beginning to go; and, secondly, the
20 endotoxin, which is one of the stimulus for it, would
21 still be around, because, in fact, the levels get higher
22 right after your treatment with antibiotics. And he's
23 just in seven hours later with full-blown disease. I
24 don't even see physiologically how the antibiotic could
25 have made any difference.

1 Q. So if I'm to understand the basis of your
2 opinion -- and that's what I'm trying to do here today --
3 is that based on the fact of his age and the short time
4 period that made, in your opinion, it less likely to have
5 a change of his course with antibiotic therapy being
6 instituted during the first admission? Is that --

7 A. Not exactly. But if I could just restate it.
8 First of all, I don't believe antibiotic therapy is
9 necessarily indicated on the first admission. I think
10 we've talk about that.

11 Q. We've talked about that.

12 A. But there are two general bases for my opinions
13 regarding causation. One is what's known about the
14 biology of how this disease expresses itself. I believe
15 he was at the far end of the spectrum on the fulminant
16 side as opposed to some other place on the spectrum, and
17 the biology of that kind of fulminant course is one in
18 which the reactivity of the body happens abruptly and
19 seemingly without any ability of medical management to
20 alter.

21 Q. Okay. Can I stop you right there?

22 A. Okay.

23 Q. Was he at the fulminant stage when he first hit
24 the emergency room on May 7th, 1992?

25 A. He did not have symptomatic purpura fulminans or

1 septic shock or kidney failure, but he's the same child,
2 and in that sense, you have -- have to look at it, at any
3 rate, as one piece which has a clinical expression that
4 is truncated into a very short time interval. And even
5 though he wasn't expressing it at the time of his
6 emergency room visit, all of the elements were in place
7 which could not be reversed by antibiotics.

8 Q. Even if he -- I guess -- I take it, it's your
9 opinion, even if those symptoms were expressing
10 themselves during the first admission, even a
11 seven-hour-and-15-minute delay of antibiotic therapy
12 wouldn't have made a difference --

13 A. No, not --

14 Q. -- or treating it early?

15 A. No, not in terms of this, because of where he
16 was on the spectrum of disease, this explosive reaction.
17 But the second basis for my opinion is a long series of
18 articles that look at antibiotics in general in
19 meningococcal infection, and outcome in general,
20 particularly bad outcome, like death. And as I read the
21 literature -- As I read the literature, I do not find any
22 correlation between outcome and the timing of antibiotics
23 or outcome and the duration of illness before antibiotics
24 except to say that in the fulminant disease, the shorter
25 you're ill, that seems to be a bad prognostic factor for

1 bad outcome.

2 Q. There is also a school of thought that would
3 differ with what *you* just told me?

4 MR. MULLER: What part of that? Because he just
5 told you about three or four things.

6 Q. Well, that earlier antibiotic therapy could make
7 a difference in a case similar to Ryan MacAdams.

8 A. I have had some -- not correspondence, but a
9 letter to the editor and responses from two sets of
10 individuals, the group in Dallas who published the
11 article in -- a pediatric infectious disease article, and
12 the group in Barcelona, Spain, that -- there was a large
13 article in the Journal of the Medical Association.

14 Q. Right.

15 A. And the group in Dallas disagreed with my
16 conclusions regarding death -- death -- and the timing of
17 antibiotics based on some studies that they referred to
18 that took place in England.

19 I believe they're interpreting these studies
20 incorrectly. And there has now been an additional study
21 from the same English group which shows no difference in
22 death rate based on the timing of antibiotics that's
23 appeared since their letter appeared.

24 So although they disagreed with me at the time
25 of our interchange, during the letter and response to the

1 letter to the editor, I think that my view is the correct
2 one.

3 Q. I understand. Could we agree there's a debate?

4 A. Well, as I said, there's been a subsequent study
5 from England by the same group that did the studies that
6 they use as their response to my letter that I believe
7 undercuts the validity of their interpretation of the
8 earlier studies.

9 Q. But they hadn't changed their opinion?

10 A. Well, the subsequent study from England came out
11 after that interchange, so I don't know what they're
12 thinking these days.

13 With regards to the group in Barcelona, I
14 actually asked for clarification of their data which had
15 to do with the use of oral antibiotics in an over
16 500-person series of meningococcal disease and outcome,
17 and their response to my letter clarified some of the
18 points of information that I didn't know about, and I
19 would think it's safe to say that they acknowledged my
20 point of view, but they expressed the hopeful belief that
21 antibiotics in some cases could alter the outcome. It
22 was not an acrimonious debate, by any means.

23 Q. Okay. You said it wasn't an acrimonious debate?
24 Friendly interchange?

25 A. Sure. Medicine is one of those things where

1 people do try to interchange and express viewpoints in
2 order to clarify things. That's the beauty of the
3 collegueship that you have in medicine.

4 Q. The one in Barcelona is the Barquet?

5 A. That's correct.

6 Q. But there is a debate among your colleagues as
7 to the prognosis with early antibiotic therapy with these
8 types of patients? I mean, that's been going on?

9 A. Well, you know --

10 Q. I know you have your opinion. I'm not debating
11 that with you. But there's a difference of opinions as
12 to whether antibiotic therapy makes a difference in this
13 type of treatment of infants, like Ryan's age, that has
14 existed through the years?

15 A. The only debate, so-called, that I've had have
16 been these two letters to the editor that I wrote
17 following the publication of articles. I believe that I
18 have overwhelming support for my point of view, and I
19 think that anybody who has a different viewpoint must
20 mount the argument based on what's known and what has
21 been shown in studies, and I think that that's incumbent
22 upon somebody who does have a different viewpoint. I
23 think I make my case based on solid information, and I
24 think my interpretation's correct.

25 Q. As to the money that you're paid in reviewing

1 cases like this, is that money that goes to you
2 personally, or do you pay it to the school or any
3 education or research or anything like that?

4 A. No, it comes to me personally, because it's done
5 on my own time.

6 Q. You don't have -- Some schools have contracts
7 where you have to submit the money to the school, and
8 things like that, but I didn't know what the case was in
9 your situation.

10 A. No. Inasmuch as it's done on my own time, it's
11 not anything that would concern the Lovelace Clinic.

12 MR. BERGEN: Okay. I believe that's all I have.
13 Thank you for your time. All right.

14 (A discussion was held off the record.)

15 Q. You mentioned you knew of Dr. Meislin when you
16 were at Arizona.

17 A. That's correct.

18 Q. Have you had any interaction with him since you
19 were at Arizona?

20 A. No. You asked me that, and the answer's no.

21 Q. Do you know that he lectures nationally on the
22 field of emergency medicine? Do you know anything about
23 what he does?

24 A. Well, I know that he's an emergency medicine
25 physician who has an academic career and lectures widely,

1 sure.

2 Q. Okay. Do you know whether or not he's respected
3 in this field of emergency medicine?

4 A. I honestly don't know. That's not my field.

5 MR. BERGEN: Okay. That's all.

6 (The deposition concluded at 5:35 p.m.)

7 (Exhibits 2 and 3 marked.)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

IN THE STATE COURT OF CHATHAM COUNTY
STATE OF GEORGIA

RYAN MacADAMS, A MINOR, BY
AND THROUGH HIS NATURAL
GUARDIAN AND PARENT AS NEXT
FRIEND, DAWN MacADAMS,

Plaintiffs,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D., AND SAVANNAH SOUTHSIDE
CLINIC, P.C.,

Defendants.

CIVIL ACTION NO,
I-97-1091-G
[JURY DEMANDED]

CERTIFICATE OF COMPLETION OF DEPOSITION

I, DANNA SCHUTTE EVERETT, CCR #139, DO HEREBY
CERTIFY that on January 25, 1999, the deposition of
MICHAEL S. RADETSKY, M.D., was taken before me at the
request of, and sealed original thereof retained by:

MR. FREDERICK S. BERGEN
Attorney for the Plaintiffs
Marist Place, Lafayette Square
123 Charlton Street, East
Savannah, Georgia 31401-4603

I FURTHER CERTIFY that copies of this Certificate
have been mailed or delivered to the following Counsel of
record and parties not represented by counsel:


MR. PETER D. MULLER
Attorney for the Defendants
BOUHAN, WILLIAMS & LEVY
Post Office Box 2139
Savannah, Georgia 31498-1001

1 I FURTHER CERTIFY that examination of this
2 transcript and signature of the witness were required by
3 the witness and all parties present. On
4 _____, a letter was mailed or delivered
5 to DR. MICHAEL S. RADETSKY regarding obtaining signature
6 of the witness.

7 I FURTHER CERTIFY that the recoverable cost of the
8 original and one copy of the deposition, including
9 exhibits, to MR. FREDERICK S. BERGEN is \$-----

10 I FURTHER CERTIFY that I did administer the oath to
11 the witness herein prior to the taking of this
12 deposition; that I did thereafter report in stenographic
13 shorthand the questions and answers set forth herein, and
14 the foregoing is a true and correct transcript of the
15 proceeding had upon the taking of this deposition to the
16 best of my ability.

17 I FURTHER CERTIFY that I am neither employed by nor
18 related to nor contracted with (unless excepted by the
19 rules) any of the parties or attorneys in this case, and
20 that I have no interest whatsoever in the final
21 disposition of this case in any court.

22 
23 DANNA SCHUTTE EVERETT, CCR, RPR
24 Certified Court Reporter #139
25 License Expires: 12/31/99

26 JOB NO. 5500-6 (DSE)
27 Proofread by: LR

1 MacAdams vs. Poleynard, et al.

2 **DEPONENT SIGNATURE/CORRECTION PAGE**

3 If there are any typographical errors to your
4 deposition, indicate them below.

5 PAGE LINE

6 _____ Change to _____

7 _____ Change to _____

8 _____ Change to _____

9 _____ Change to _____

10 _____ Change to _____

11 Any other changes to your deposition are to be listed
12 below with a statement as to the reason for such
13 change.

14 PAGE LINE CORRECTION REASON FOR CHANGE

15

16

17

18

19 I, **MICHAEL S. RADETSKY, M.D.**, do hereby certify that
20 I have read the foregoing pages of my testimony as
21 transcribed, and that the same is a true and correct
22 transcript of the testimony given by me in this
23 deposition except for the changes made.

21

22 _____
23 **MICHAEL S. RADETSKY, M.D.**

23

24 JOB NO. 5500-6 (DSE)
25 Date Taken: January 25, 1999
Proofread by: LR

IN THE STATE COURT OF CHATHAM COUNTY
STATE OF GEORGIA

RYAN MACADAMS, A MINOR, BY
AND THROUGH HIS NATURAL
GUARDIAN **AND** PARENT AS NEXT
FRIEND, DAWN MACADAMS,

Plaintiffs,

VS.

BLAKE CHRISTOPHER POLEYNARD,
M.D., AND SAVANNAH SOUTHSIDE
CLINIC, F.C.,

Defendants.


] 1 1 1 1 1 3 1 1 1 1 1 1 1

CIVIL ACTION NO.
I-97-3091-G
[JURY DEMANDED]

NOTICE TO TAKE DEPOSITION

TO: Michael S. Radetsky, M.D.
Department of Pediatrics
Lovelace Medical Center
5400 Gibson Boulevard, SE
Albuquerque, New Mexico 87108

Please take notice that counsel for the Plaintiff in the above-styled case will take the Deposition of Michael S. Radetsky, M.D. at Bean & Associates Court Reporters located at 500 Marquette Northwest, Suite 280, Albuquerque, New Mexico, on the 25th day of January, 1999 beginning at 2:30 p.m. The Deposition will be taken before a Certified Court Reporter and Notary Public. The Deposition will be taken pursuant to Georgia Civil Practice Act (Code §§9-11-16 and 9-11-30) and for the purpose of discovery and preservation of testimony for trial. The oral examination will continue from day to day until its completion. You may attend and examine, as allowed by law.



Michael S. Radetsky, M.D. is further ordered to bring the following:

1. Letters received from Peter D. Muller, or any member *of* the law firm of Bouhan, Williams & Levy, L.L.P., or any representative of Illinois National Insurance Company relating to your review of the materials relating to the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
2. Medical Records which you have reviewed to formulate your opinions in the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
3. Materials which you have reviewed to formulate your opinions in the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
4. Medical literature which you have reviewed in formulating your opinions in the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and

Savannah Southside Clinic, P.C.

5. Reports, memorandums, written letters, or any other writing which expresses your opinions in connection with the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
6. Records reflecting time spent in reviewing the materials in formulating your opinions in the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
7. Invoices submitted for payment for your expert review and copies of payments received from Peter D. Muller, or any member of the law firm of Bouhan, Williams & Levy, L.L.P., or any representative of Illinois National Insurance Company relating to your review of the materials relating to the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher Poleynd, M.D. and Savannah Southside Clinic, P.C.
8. Depositions which you have reviewed in the case of Ryan MacAdams, a Minor, By and Through His Natural Guardian and Parent, Dawn MacAdams vs. Blake Christopher

Poleynard, M.D. and Savannah Southside Clinic, P.C.

This 20th day of January, 1999..


JOSEPH B. BERGEN

Ga. Bar No. 054200

and

FREDERICK S. BERGEN

Ga. Bar No. 054160

By: 

Frederick S. Bergen

Ga. Bar No. 054160


123 East Charlton Street
Savannah, Georgia 31401
(912) 233-6600

CERTIFICATE OF SERVICE

This is to certify that I have this day served counsel for all parties with a true copy of the foregoing pleading by placing a copy of same in the United States Mail with adequate postage thereon to insure prompt delivery to:

Peter D. Muller, Esquire
BOUHAN, WILLIAMS & LEVY, L.L.P.
Attorneys at Law
Post Office Box 2139
Savannah, Georgia 31402-2139

This 20th day of January, 1999.



Frederick S. Bergen

123 East Charlton Street
Savannah, Georgia 31401
(912) 233-6600

is w/o = meningococcemia
c meningitis

1

5/2/92 Seen ER St. Joseph Hospital

17:22 RN: Alert T=104.3

17:30 Tylenol supp.

Frog wet diapers
Skin "wax"

18:30

MD: Dr. Perez: conscious, alert, tracking,
appropriate response to
noxious stimulus; motor
tone (+).

Skin: (+) turgor, warm, dry,
without cyanosis, without
petechiae. No rash is
present.

18:07 T=101.3 (R)

A: ur. & syndrome.

Pulse Ox - (+) big toe - 98%

19:12

LAB

491 / 11.2 / 9600
33 (445, 293, 254)

Dr. Perez
leaves @
19:00, Dr.
POLEYMAN
assumes
care

UA - Sp gr. 1.007.
D.p (+).

Home instructions:

SpO2 (RA) 98%

Push fluids


Tylenol

Flu Family MD if not well in
2 or 3 d.

call or return if any problem

20:15

D/c ~~MD~~ 20:15



5/8/92 St. Joseph Hosp ER.

03:32 Hx: "Since discharge several hours ago, the patient has developed a shrill cry + petechial rash.

04:00 + 04:15 120cc plasma given.

04:00 LR fluid bolus

04:13 LAB

156⁰⁰⁰ / 10.6.
31 / 5,000
(73, 28B, 614)

BC - N. meningitidis.

03:54 ABG - 7.279 / 24.4 / 85 (95%) / -12.7

006:00 Transfer to Memorial Medical Center

Memorial Medical Center.

CSF - RBC 1305

WBC 48 (67% pmn)

gluc 35

prot 74.

LA ⊖

IN THE STATE COURT OF CHATHAM COUNTY

STATE OF GEORGIA

RYAN MACADAMS, A Minor, By
and Through His Natural
Guardian and Parent as Next
Friend, DAWN MACADAMS,

Plaintiff,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D., FERNANDO JAVIER PEREZ,
M.D., and SAVANNAH SOUTHSIDE
CLINIC, P.C.,

Defendants.


CIVIL ACTION NO. I971091G

DEFENDANT SAVANNAH SOUTHSIDE CLINIC, P.C.'S SUPPLEMENTAL
RESPONSES TO PLAINTIFFS' FIRST INTERROGATORIES

COMES NOW Defendant SAVANNAH SOUTHSIDE CLINIC, P.C., and supplements
its responses to Plaintiffs' First Interrogatories as follows:

1. (a) Michael S. Radetsky, MD CM
Department of Pediatrics
Loveiace Medical Center
5400 Gibson Boulevard SE
Albuquerque, NM 87108
(505) 262-3542

Dr. Radetsky is expected to testify on the issue of standard of care and
causation, based upon various facts which have been presented in medical records
and depositions.




Based upon the test results and findings of Dr Perez and Dr. Poleynard, Dr Poleynard acted within the standard of care in his diagnosis, treatment, and discharge of Ryan MacAdams.

On the matter of causation, Dr. Radetsky is expected to testify that there ~~was~~ no causal connection between Ryan MacAdams not being diagnosed with meningococcal infection or treated with antibiotics during his first ER visit, and his development of orthopedic and other problems. Treatment with antibiotics during the first visit would not have prevented such problems. Also, it is likely that the orthopedic problems were unrelated to the meningococcal infection.

DATED this 4 day of January, 1999.

BOUHAN, WILLIAMS & LEVY LLP

By: 

PETER D. MULLER
Georgia State Bar No. 528233
ATTORNEYS FOR DEFENDANT
SAVANNAH SOUTHSIDE CLINIC,
P.C.

Post Office Box 2139
Savannah, Georgia 31402-2139
(912) 236-2491

IN THE STATE COURT OF CHATHAM COUNTY

STATE OF GEORGIA

RYAN MACADAMS, A Minor, By
and Through His Natural
Guardian and Parent as Next
Friend, D A W MACADAMS,

Plaintiff,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D., FERNANDO JAVIER PEREZ,
M.D., and SAVANNAH SOUTHSIDE
CLINIC, P.C.,

Defendants.

CIVIL ACTION NO. I971091G


CERTIFICATE OF SERVICE

I, PETER D. MULLER, **do** hereby certify that I have this day served a true and correct copy of the above and foregoing DEFENDANT SAVANNAH SOUTHSIDE CLINIC P.C.'S SUPPLEMENTAL RESPONSES TO PLAINTIFFS' FIRST INTERROGATORIES by causing same to be placed in the United States mail, postage prepaid, to:

Frederick S. Bergen, Esquire
123 E. Charlton Street
Savannah, GA 31401

This 1st day of January, 1999.

BOUHAN, WILLIAMS & LEVY LLP

By: 

PETER D. MULLER

Post Office Box 2139
Savannah, Georgia 31402-2139
(912) 236-2491

IN THE STATE COURT OF CHATHAM COUNTY

STATE OF GEORGIA

RYAN MACADAMS, A Minor, By
and Through His Natural
Guardian and Parent as Next
Friend, DAWN MACADAMS,

Plaintiff,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D. FERNANDO JAVIER PEREZ,
M.D. SAVANNAH SOUTHSIDE
CLINIC, P.C.

Defendants.

CIVIL ACTION NO. 19910910

DEFENDANT SAVANNAH SOUTHSIDE CLINIC, P.C.'S SUPPLEMENTAL
RESPONSES TO PLAINTIFFS' FIRST INTERROGATORIES

COMES NOW Defendant SAVANNAH SOUTHSIDE CLINIC, P.C., and supplements
its responses to Plaintiffs' First Interrogatories as follows:

1. (a) Michael S. Radetsky, MD CM
Department of Pediatrics
Loveiace Medical Center
5400 Gibson Boulevard SE
Albuquerque, NM 87108
(505) 262-3542


Dr. Radetsky is expected to testify on the issue of standard of care and
causation, based upon various facts which have been presented in medical records
and depositions.

Based upon the test results and findings of Dr Perez and Dr. Poleynard, Dr Poleynard acted **within** the standard of w e in his diagnosis, treatment, and discharge of Ryan MacAdams.

On the matter of causation, Dr. Radetsky is expected to testify that there **was** no causal connection between Ryan MacAdams not being diagnosed with meningococcal infection or treated with antibiotics during his first ER visit, and his development of orthopedic and other problem. Treatment with antibiotics during the first visit would not have prevented such problems. Also, it is likely that the orthopedic problems were unrelated to the meningococcal infection.

DATED this 4 day of January, 1999.

BOUHAN, WILLIAMS & LEVY LLP

By: 
PETER D. MULLER
Georgia State Bar No. 528233
ATTORNEYS FOR DEFENDANT
SAVANNAH SOUTHSIDE CLINIC,
P.C.

Post Office Box 2139
Savannah, Georgia 31402-2139
(912) 236-2491

IN THE STATE COURT OF CHATHAM COUNTY

STATE OF GEORGIA

RYAN MACADAMS, A Minor, By
and Through His Natural
Guardian and Parent as Next
Friend, D A W MACADAMS,

Plaintiff,

vs.

BLAKE CHRISTOPHER POLEYNARD,
M.D. FERNANDO JAVIER PEREZ,
M.D. and SAVANNAH SOUTHSIDE
CLINIC, P.C.,

Defendants.

CIVIL ACTION NO. I971091G


CERTIFICATE OF SERVICE

I, PETER D. MULLER, do hereby certify that I have this day served a true and correct copy of the above and foregoing DEFENDANT SAVANNAH SOUTHSIDE CLINIC P.C.'S SUPPLEMENTAL RESPONSES TO PLAINTIFFS' FIRST INTERROGATORIES by causing same to be placed in the United States mail, postage prepaid, to:

Frederick S. Bergen, Esquire
123 E. Charlton Street
Savannah, GA 31401

This 4th day of January, 1999.

BOUHAN, WILLIAMS & LEVY LLP

By: 

PETER D. MULLER

Post Office Box 2139
Savannah, Georgia 31402-2139
(912) 236-2491

CURRICULUM VITAE

NAME:

MICHAEL S RADETSKY MD CM

DATE AND PLACE OF BIRTH:

November 19, 1945
Denver, Colorado
USA

PROFESSIONAL ADDRESS:

Department of Pediatrics
Lovelace Medical Center
5400 Gibson Boulevard SE
Albuquerque, NM 87108
Telephone (505) 262-3542

CURRENT POSITION

Chairman, Department of Pediatrics
Director of Newborn Medicine
Consultant, Pediatric Infectious Disease
Consultant, Pediatric Critical Care
Lovelace Health System
Albuquerque, New Mexico

Attending Physician
Department of Pediatrics
University of New Mexico Health Science
Center

Clinical Professor of Pediatrics
University of New Mexico School of Medicine
Albuquerque, New Mexico

Fellow, Center for Public Policy and
Contemporary Issues
University of Denver
Denver, Colorado

JOURNAL EDITOR

Editor



Section on Pediatric and Neonatal Infections
Current Opinion in Infectious Diseases
1993-1996

JOURNAL REVIEWER

Pediatric Infectious Disease Journal
American Journal of Diseases of Children
Journal of the American Medical Association
Pediatrics
Journal of Pediatrics
Pediatric Emergency Care
Yearbook of Pediatrics

UNDERGRADUATE EDUCATION:

Harvard College - A.B. cum laude, 1967

POSTGRADUATE ACTIVITIES

Harvard Law School - 1967-1968
(Courses passed. Leave of Absence)

United States Peace Corps, Malariologist
Thailand - 1968-1969

Alternative National Service (Conscientious
Objection) - Boston Floating Hospital for
Children/Tufts New England Medical Center -
1970-71

PREMEDICAL EDUCATION

University of Colorado
Boulder, CO - 1972-1973

MEDICAL EDUCATION:

McGill University - Montreal, Quebec
Canada - M.D.C.M. (Honors), 1973-1977

ROTATING INTERNSHIP:

San Francisco General Hospital, 1977- 1978

PEDIATRIC INTERNSHIP:

University of Colorado School of Medicine
Denver, Colorado, 1978-1979

RESIDENCY IN PEDIATRICS:

University of Colorado School of Medicine
Denver, Colorado, 1979-1981

FELLOWSHIP TRAINING IN PEDIATRIC INFECTIOUS DISEASES

University of Colorado School of
Medicine/The Children's Hospital
Denver, Colorado, 1980-1982

PRIOR POSITION:

1991-1993

Director, Pediatric Critical Care Services
Consultant, Pediatric Infectious Disease
Kaiser Permanente
Sacramento, CA

Attending Pediatric Intensivist
University of California Medical Center
Sacramento California

Pediatric Intensivist
Sutter Memorial Hospital
Sacramento California

Consultant, Pediatric Infectious Diseases
University of California Medical Center
Sacramento California

Clinical Professor of Pediatrics
University of California School of Medicine
Davis, California

PRIOR POSITION:

1989-1991

Assistant Director of Pediatrics
Director of Pediatric Hospital Services
Director, Pediatric Critical Care
Consultant, Pediatric Infectious Disease
Denver General Hospital

Attending Physician
Ambulatory Pediatric Clinic
Denver General Hospital

Attending Physician
Intensive Care Unit
The Childrens Hospital of Denver

Visiting Professor in Pediatrics
Fitzsimmons Army Medical Center
Denver, Colorado

Associate Professor of Pediatrics
University of Colorado School of Medicine
Denver, Colorado

Lecturer in Ethics
Graduate School of Public Affairs
University of Colorado, Denver
Denver, Colorado

Lecturer in Medicine and Social Policy
University of Denver
Denver, Colorado

PRIOR POSITION:
1987-1989

Director of Pediatric Critical Care Services
Tucson Medical Center
Tucson, AZ

Chief of Pediatric Critical Care
University Medical Center
Tucson, **AZ**

Consultant in Pediatric Infectious Disease
Tucson Medical Center, and
University Medical Center
Tucson, AZ

Clinical Associate Professor of Pediatrics
University of Arizona School of Medicine
Tucson, AZ

PRIOR POSITION:
1982-1987

Associate Director
Infectious Disease Service
The Children's Hospital

Denver, Colorado

Attending Physician
Intensive Care Unit
The Children's Hospital of Denver

Assistant Professor of Pediatrics
University of Colorado School of Medicine
Denver, Colorado

Visiting Lecturer in Medical Ethics
and Social Policy
Department of Public Affairs
University of Denver
Denver, Colorado

Lecturer in Ethics
Graduate School of Public Affairs
University of Colorado, Denver
Denver, Colorado

PRIVATE PEDIATRIC PRACTICE

Childrens Medical Center
1575 Vine Street
Denver CO
(Parttime coverage 1981-1987)

PROFESSIONAL LICENSURE:

State of New Mexico

State of Colorado

State of California (inactive)

State of Arizona (lapsed)

Medical Council of Canada

BOARD CERTIFICATION:

American Board of Pediatrics - 1983

Pediatric Critical Care
American Board of Pediatrics - 1987

Recertification - 1995

Pediatric Infectious Disease
American Board of Pediatrics - 1995

NATIONAL FACULTY:

Pediatric Advanced Life Support
American Heart Association

HONORS AND AWARDS:

Gold Medal Winner, Thames **Cup**
Henley Royal Regatta, England - 1966

Haines' Memorial Award for Excellence in
Athletics - Harvard College - 1967

Alexander Stewart Prize for Medical School
Excellence, McGill Medical School, 1977.

Surgery Prize, McGill University, 1977,

Kaiser-Permanente Clinical Teaching Award
Finalist, University of Colorado School of
Medicine, 1983.

Kaiser-Permanente Clinical Teaching Award
Finalist, University of Colorado School of
Medicine, 1984.

Kaiser-Pemanente Clinical Teaching Award
Finalist, University of Colorado School of
Medicine, 1985.

The Gary Way Award for Outstanding
Teaching
Department of Pediatrics
The Children's Hospital
University of Colorado
School of Medicine, 1985.

Kaiser-Pemanente Teaching Award
Finalist in the Basic Sciences
University of Colorado School of Medicine,

1986.

Commencement Speaker
University of Colorado School of Medicine
Hooding and Oath Ceremony, 1986.

Pediatric Housestaff Special Award
Department of Pediatrics
University of Colorado School of Medicine, 1987

Dean's List for Excellence in Teaching in the
Clinical Sciences Award
University of Arizona College of Medicine,
Tucson, AZ, 1988

Finalist, Clinical Teaching Award
University of Arizona College of Medicine,
Tucson, AZ 1989

Commencement Speaker
University of Colorado School of Medicine
Hooding and Oath Ceremony, 1989

Attending Physician of the Year
Family Practice Residency Program
University of Arizona College of Medicine,
1989

Pediatric Residents' Teaching Award
University of Arizona College of Medicine,
1989

The Gary Way Award for Outstanding
Teaching
Department of Pediatrics
The Children's Hospital
University of Colorado School of Medicine,
1990.

Honorary Faculty Membership
Alpha Omega Alpha Honor Medical Society
University of Colorado School of Medicine
1991

Joseph W. St. Geme Jr. MD Award for
Exceptional Ability in Promoting the Overall
Mission of the School of Medicine
University of Colorado School of Medicine
1991

Excellence in Teaching Award
Medical Student Council
University of Colorado School of Medicine
1992

Clinical Teacher of the Year
Department of Pediatrics
University of California School of Medicine -
Davis, 1992

Clinical Teacher of the Year
Department of Pediatrics
University of California School of Medicine -
Davis, 1993

Inaugural Recipient
William and Daniel Gelfand Lectureship
The Childrens Hospital/University of Colorado
1994

Alpha Omega Alpha Annual Lectureship
University of Arizona School of Medicine
1995

Selected
The Best Doctors in America: Central Region
1996-1997

Sydney Gellis Lectureship
Boston Floating Hospital for Children
Tufts University
1998

Selected
Best Doctors in America
1999

VISITING PROFESSORSHIPS:

Hospital for Sick Children, Great Ormond
Street, London, England
1982

Hospital for Sick Children, Great Ormond
Street, London, England
1985

Duke University School of Medicine, Durham,
NC
1987

Hospital for Sick Children, Great Ormond
Street, London, England
1989

University of Florida School of Medicine,
Jacksonville, Florida
1990

Akron Children's Hospital, Akron, Ohio
1990

Cincinnati Children's Hospital, Cincinnati,
Ohio 1991

University of Minnesota School of Medicine
1991

Aglaia Kyriakou Children's Hospital
Athens, Greece (invited only)
1991

TKC Medical Center
Honolulu, Hawaii
1991

Children's Hospital
Omaha, Nebraska
1993

PROFESSIONAL ORGANIZATIONS

Infectious Disease Society of America

Pediatric Infectious Disease Society

Alpha Omega Alpha Honorary Fraternity

American Society for Law, Medicine and
Ethics

PUBLICATIONS:

Journals

- 1) **Radetsky MS.** Recapturing the spirit in medicine. *N Engl J Med* 1978; 298:1142.
- 2) **Radetsky MS,** Istre GR, Johansen TL, Parmelee SW, Eauer BA, Wiesenthal AM, Glode MP. Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre, *Lancet* 1981; 2:771-773.
- 3) **Radetsky MS.** A diagnostic approach to Epstein-Barr virus infections. *Pediatr Infect Dis* 1982; 1:425-429.
- 4) **Radetsky MS.** Personal view: the hero in medicine. *Brit Med J* 1983; 287:493.
- 5) **Radetsky M,** Todd JK. Criteria for the evaluation of new diagnostic tests. *Pediatr Infect Dis* 1984;3:461-466.
- 6) **Radetsky MS.** The clinical evaluation of the febrile infant. *Primary Care* 1984; 11:395-405.
- 7) **Radetsky M,** Wheeler RC, Roe MH, Todd JK. Comparative evaluation of kits for rapid diagnosis of group A streptococcal disease. *Pediatr Infect Dis* 1985; 4:274-281.
- 8) **Radetsky M.** The rise of the academic clinician. *Am J Dis Child* 1985; 139:861.
- 9) **Radetsky M.** Sudden intimacies. *JAMA* 1985;254:1361; reprinted in: Dan BB, Young RK (eds). *A Piece of My Mind*, 1988; New York: AA Knopf.

- 10) **Radetsky M.** Laboratory evaluation of acute diarrhea. *Pediatr Infect Dis* 1986; 5:230-238.
- 11) **Radetsky M,** Wheeler RC, Roe MH, Todd JK. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. *J Clin Microbiol* 1986;24:600-606.
- 12) **Radetsky M,** Soloman JA, Todd JK. Identification of streptococcal pharyngitis in the office laboratory: reassessment of new technology. *Pediatr Inf Dis* 1987; 6: 556-563.
- 13) **Radetsky M.** Duration of treatment in bacterial meningitis: a historical inquiry. *Pediatr Infect Dis J* 1990; 9: 2-9.
- 14) **Radetsky M.** Duration of Symptoms and Outcome in Bacterial Meningitis: An Analysis of Causation and the Implications of a Delay in Diagnosis. *Pediatr Infect Dis J* 1992;11: 694-8.
- 15) **Radetsky M.** Pediatric and neonatal infections: Editorial overview, *Curr Opinion Infect Dis* 1993;6:545-6.
- 16) **Radetsky M.** Infectious disease emergencies. *Curr Opinion Pediatr* 1994; 6: 310-6.
- 17) **Radetsky M.** The timing of antimicrobial therapy and outcome in serious bacterial infections. *Curr Opinion Infect Dis* 1994;7:341-4.
- 18) **Radetsky M.** The laboratory evaluation of newborn sepsis. *Curr Opinion Infect Dis* 1995;8:191-9.
- 19) **Radetsky M.** Use of antimicrobials for the prevention of recurrent urinary infection in children. *Dialogues in Pediatric Urology* 1995;18:7-8.
- 20) **Radetsky M.** The febrile infant and the assumption of risk. *Curr Opinion Infect Dis* 1996;9:171-5.
- 21) **Radetsky M.** The discovery of penicillin. *Pediatr Infect Dis J* 1996;15:811-8.
- 22) **Radetsky M.** The newborn at risk for serious infections. In: Britton JR (ed). Issues related to early discharged newborn infants and their mothers. *Clinics in Perinatology*, 1998;25:327-34.

23) **Radetsky M.** The emerging spectrum of tickborne infections. *Curr Opin Infect Dis* 1998;11:3 13-8.

Letters to the Editor

1) **Radetsky M.** Timing of therapy for meningococcal infection. *Pediatr Infect Dis J* 1997;16:540-1.

2) **Radetsky M.** Prognostic factors in meningococcal disease. *JAMA* 1997;278:1658.

3) **Radetsky M.** The social missions of academic health centers. *New Engl J Med* 1998;338:1232.

4) **Radetsky M.** On the front lines of medicine. *Time*, November 2, 1998;152 (18):22.

Book Chapters

1) **Radetsky M.** A clinical approach to the diagnosis of streptococcal pharyngitis. In: Barkin RM (ed.) *The Emergently Ill Child*, Rockville MD, Aspen Publishers, 1987.

2) **Radetsky M.** The Nature and History of Medical Ethics. In: Nussbaum E. (ed.) *Pediatric Intensive Care*, 2nd ed., 1989, Mt. Sisco NY, Futura Publishing. Reviewed in: *Arch Dis Child* 1990;65:816.

3) **Radetsky M.** The Doctrine of Informed Consent. In: Nussbaum E. (ed.) *Pediatric Intensive Care*, 2nd ed., 1989, Mt. Sisco NY, Futura Publishing. Reviewed in: *Arch Dis Child* 1990;65:816.

4) **Radetsky M.** Decisions to Limit, Diminish, or Withdraw Therapy. In: Nussbaum E. (ed.) *Pediatric Intensive Care*, 2nd ed., 1989, Mt. Sisco NY, Futura Publishing. Reviewed in: *Arch Dis Child* 1990;65:816.

5) **Radetsky M.** The Definition and Determination of Death. In: Nussbaum E. (ed.) *Pediatric Intensive Care*, 2nd ed., 1989, Mt. Sisco NY, Futura Publishing. Reviewed in: *Arch Dis Child* 1990;65:816.

6) **Radetsky M.** Enterobacteriaceae. In: Patrick C (ed.) *Infections in Immunocompromised Infants and Children*, 1992, New York, Churchill Livingstone.

- 7) **Radetsky M.** The Use of Antimicrobials and a Synopsis of Infectious Disease in the Pediatric Intensive Care Unit. In: Fuhrman BP, Zimmerman JJ. (eds.) Pediatric Critical Care, 1992, St. Louis, Mosby Year Book
- 8) **Radetsky M.** Exanthematous Viral Infections. In: McAnarney ER, Kreipe RE, Orr DP, Comerci GD (eds.) Textbook of Adolescent Medicine, 1992, Philadelphia, W.B. Saunders.
- 9) **Radetsky M.** Streptococcal Infections. In: Burg FD, Ingelfinger JR, Wald ER (eds.) Current Pediatric Therapy 14, 1993, Philadelphia, W.B. Saunders.
- 10) **Radetsky M.** Streptococcal Infections. In: Burg FD, Ingelfinger JR, Wald ER (eds.) Current Pediatric Therapy 15, 1995; Philadelphia, WB Saunders
- 11) **Radetsky M.** Staphylococcal Infections. In: Burg FD, Ingelfinger JR, Wald ER (eds.) Current Pediatric Therapy 15, 1995; Philadelphia, WB Saunders..
- 12) **Radetsky M, Overturf GD.** Epstein-Barr Infections in Adolescents and Young Adults. In: Overturf GD, Jacobs RF (eds.). Adolescent Medicine: Viral Infections of the Adolescent, 1995, Philadelphia, Hanley and Belfus.
- 13) **Radetsky M.** Antibiotic; use in pediatric critical care. In: Fuhrman BP, Zimmerman JJ. (eds.) Pediatric Critical Care, 2nd ed., 1998, St. Louis, Mosby Year Book.
- 14) **Radetsky M.** Shigella Infections. In: Stockman JA, Lohn JA (eds.) Ambulatory Pediatrics, Philadelphia, WB Saunders (in press).

D) Abstracts

- 1) **Radetsky MS, Glode MP, Istre GR, Lauer BA, Wiesenthal AM.** Emergence of multiply resistant pneumococcus. Presented at the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, November 1981.
- 2) Todd JK, Parmelee SW, **Radetsky M.** Antimicrobial combination interactions with Streptococcus pneumoniae and Haemophilus influenzae. Presented at the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami, October 1982. Abstract 222.
- 3) Wheeler RC, **Radetsky MS**, Roe MH, Todd JK. Comparison of two candida antigen detection systems for identifying patients with disseminated candidiasis. Presented at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, October 1985. Abstract 760.